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INTRODUCTION 
The name “mass spectrometry” is a misnomer of sorts. The mass is not what is measured; instead, 
mass spectrometry determines the mass-to-charge (m/z) ratio or a property related to m/z. A mass 
spectrum is a plot of ion abundance versus m/z, although in many cases the x-axis is labelled 'mass' 
rather than m/z [1]. Basically, these few rows depicts mass spectrometry (MS) as a highly simple 
and intuitive tool for all kinds of users. However, for mass spectrometry users this discipline is still 
full of daily challenges. In particular, mass spectrometry was born in the 19
th
 century during studies 
focused on gas discharges. Moreover, a key chapter in the mass spectrometry story was the 
introduction of electrospray ionization (ESI), which allowed the analysis of proteins, biomolecules 
and large organic molecules, impraticable with the previously conventional ionization techniques. 
Fenn and Tanaka were awarded with the Nobel Prize in the 2002 for ESI development. ESI is also 
the ion source used in this manuscript.  
The ability of mass spectrometry to efficiently generate intact biomolecular ions in the gas phase 
has led to its widespread application in metabolomics, proteomics, biological imaging, biomarker 
discovery and clinical assays. Advances in MS technologies, high resolution liquid phase 
separations, and informatics/bioinformatics for large scale data analysis have made MS-based 
proteomics an indispensable research tool with the potential to broadly impact biology and 
laboratory medicine, attesting the importance of mass spectrometry in everyday life. As a result, 
high accuracy mass measurements coupled with improved sample preparation and multi-
dimensional liquid separation methods are enabling to accomplish the task of determining structures 
of biomolecules and structure/function relationships at sensitivity levels adequate for proteins and 
peptides [2].  
In addition, several data shown in this manuscript have been a part of a collaboration between the 
University of Parma and the University of Southern Denmark under the supervision of Prof. M. 
Careri and Prof. M. R. Larsen. (Project Title: “Quantitative comparison of proteome and PTM-ome 
of platelet derived microparicles using different agonist stimulations”). 
This PhD thesis has been divided in four main sections. In particular, the first section is composed 
by fourth chapters showing an overview of the main components of a mass spectrometer such as ion 
sources, mass analyzers, fragmentation techniques, bottom up strategies, focus on a mass 
spectrometer used for our proteomics experiments as first chapter. An introduction of mass 
spectrometry-based  proteomics was therefore summarized in the first chapter. In the second chapter 
of the first section, key aspects of phosphoproteomics were discussed starting from enrichment-
based protocols as TiO2, IMAC (employed in our phospoproteins investigation), SAX, SCX and 
 2 
 
ERLIC. Fragmentation strategies and mass spectra interpretation in phosphopeptide experiments 
were shown. Phosphoproteomics was discovered to be implicated in relevant signaling pathways. 
Phosphoproteins were reported in this thesis as known and mostly studied PTM (post-translational 
modifications) as well as glycoproteomics, described in the third chapter of the first section. 
Glycosylation is deeply implicated in several physiological and pathological process. In particular, 
protein sialylation, which was analyzed in a specific type of cells in this work, was found to be 
involved in cancer metastasis. Furthermore, typical enrichment methods such as HILIC (used in our 
glycoproteomics experiments) were reviewed. MS is a challenge in glycoproteomics due to the 
heterogenous structures of glycans linked to peptides; this aspect was specifically investigated in 
this study. In the fourth chapter main quantitative proteomics approaches were presented. Protein 
quantitation was found to be very useful in order to compare different biological condition, different 
time points especially in organ development, cancer progression and cell stimulation. In addition, 
iTRAQ-based proteomics was demonstrated to be widely used as quantitative tool in comparative 
analysis.  
In the second section, an iTRAQ-based quantitative proteomics experiment was performed in order 
to compare the protein content of platelet derived microparticles (PMPs) obtained by differentially 
activated platelet samples. PMPs are a population of vesicles generated upon platelet activation by 
various stimuli known to be involved in several physiological and pathological processes. In 
particular, platelet activation was carried out using known physiological platelet stimulants as ADP, 
thrombin and collagen. Our proteomics analysis allowed the quantification of 3383 proteins, of 
which 428 membrane and 131 soluble proteins were found as significantly different in at least one 
of the analyzed conditions chosing thrombin, which is mostly used to generate PMPs in vitro, as 
control. Our findings suggest a biological link between agonist strength and proteins associated to 
platelet mediated processes such as activation and degranulation. These data may provide new 
insights for understanding PMPs biological role and formation. In the appendix, the datasets of the 
significantly changed membrane and soluble proteins after cluster analysis were reported.  
Moreover, in the third section the same approach was used to study the phosphoproteome and the 
glycoproteome of PMPs. In addition, glycoproteome was divided into N-sialiome and N-
glycoproteome by performing two different enrichment strategies as TiO2 and HILIC. 
Phosphopeptides were separated into monophosphorylated and multiply phosphorylated peptides 
using SIMAC. Furthermore, our pipeline allowed the identitification of 1225 unique 
phosphopeptides assigned to 614 phosphoproteins and 1245 unique glycosylated peptides assigned 
to 533 unique glycoproteins. Our proteomics approach unveiled that glycosylation on focal 
adhesion related protein, in particular on integrins such as αIIbβ3, was directly related to the 
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physiological agonist strength used for platelet activation. Collectively, our MS-based quantitative 
study provided an overview of the PTM-ome of PMPs, which can be of high interest to reveal 
biological insights about platelet response to stimuli. In the fourth chapter, MS-based proteomics 
was applied to the analysis of allergenic proteins in wine samples: for this purpose, different sample 
treatment protocols for the liquid chromatography (LC)-ESI-MS/MS analysis of potential residuals 
of ovalbumin and caseins added to red wines were investigated. In particular, attention was paid to 
the simultaneous detection and quantitation of fining agent residues such as ovalbumin, - and -
casein, in wine samples. The different sample treatment methods were compared in terms of protein 
recovery. Finally, the chosen method was applied for the analysis of 20 commercial red wine 
samples.  
This PhD. thesis has shown that mass spectrometry has evolved to become an irreplaceable 
technique to investigate biological and food samples.   
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1. MASS SPECTROMETRY  
Mass spectrometry (MS) has become the technology of choice in several disciplines including 
proteomics. MS allows the determination of accurate mass of ionized compounds. The analytes are 
ionized into an ion source, mainly electrospray and matrix assisted-ionization, accelerated and 
deflected by electric and magnetic fields which provide their mass to charge ratio (m/z). Every kind 
of mass spectrometer is formed by three different components: ion source, mass analyzer and 
detector. Ion sources are able to create gas phase-ions from the investigated compounds. Gas phase 
ions, which are separated by mass-to-charge ratio into the mass analyzer, are finally revealed by the 
detector and the output is then computationally processed enabling the generation of a mass 
spectrum based on the acquired signals.  
Ion sources - The most commonly used ion sources in proteomics are matrix-assisted laser 
desorption ionization (MALDI) and electrospray ionization (ESI) [1]. Due to its ability of 
preserving the main structure of compounds without any possibility of fragmentation, MS has 
raised great interest as a tool for analyzing large bio-molecules such as proteins. In the MALDI 
ionization process, laser radiation hits the matrix, which is co-crystalized with samples. The matrix 
donates a charge to the analyte by inducing the sublimation of matrix-analytes sample [2]. Ions are 
mostly present as singly charged species. Sample preparation and not homogeneous deposition may 
affect the reproducibility, so that scarce precision is the main disadvantage of this technique; despite 
that, MALDI is very useful because it allows the analysis of compounds with very high MW 
(300.000 Da). In the ESI strategy, a strong electric field allows the evaporation of the sample 
solution into gas phase giving highly charged droplet. During this evaporation step, the analyte is 
transferred to the gas phase and attracted by opposite charges MS lenses [3]. ESI process is suitable 
for the analysis of large biomolecules giving multiply charged species. In addition, ESI can be 
coupled to separation and fractionation techniques such as liquid chromatography (LC). This 
configuration is very proficient in analyzing different sizes of molecules with various polarities in a 
complex sample mixture such as whole cell lysates.           
Mass analyzers - Mass analyzer is responsible to separate gas phase ions according to their 
mass-to-charge ratio. Mass analyzer can be used in scanning and selecting mode; in scanning mode, 
it analyzes a determined mass-to-charge ratio range providing a “full scan” spectrum, whereas in 
selecting mode, it allows the isolation of a specific analyte, filtering it out from the rest of the ions. 
There are several types of mass analyzers: 1. quadrupole; 2. ion trap (linear or 3-dimensional); 3. 
time of flight (TOF); 4. Fourier transform-based mass analyzer (orbitrap). Those mass analyzers 
separate mass-to-charge ratio signals based on different mechanisms. Fourier transform-based mass 
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analyzers have the highest mass resolution (up to 1,000,000). However, quadrupoles and ion traps 
are the fastest and most sensitive analyzers, but their mass accuracy and resolution is quite low 
(~1,000).  
1. Quadrupole mass analyzer is composed of four parallel metal rods in which a radio frequency 
voltage is applied between one pair of rods and the other, generating an oscillating electric field. 
Only ions of a certain m/z ratio have a stable oscillating trajectory and will reach the detector, the 
other ions have unstable trajectories and will hit the rods without any possibility of being detected. 
2.Ion trap mass analyzers. Ion trap is similar to the quadrupole mass filter, but the ions are trapped 
before their ejection into a zone defined by a ring electrode (usually connected to the radio 
frequency potential) and two endcap electrodes (typically connected to direct current or auxiliary 
alternating current potentials). 
3. Time of flight (TOF) mass analyzer that separates ions on the bases of their masses, by 
accelerating them in an electric field. TOF mass analyzer can be in a linear or in a reflectron mode, 
and this affects its mass resolution. 
4. Fourier transform ion cyclotron resonance (FTICR) and orbitrap mass analyzer. These types of 
mass analyzers are the ones capable of achieving the highest resolutions. They resolve the m/z of 
the analytes based on their frequency of oscillation. The orbitrap is the most recent mass analyser 
developed.  
Detectors - The ions separated by the mass analyzer are directed to the detector and 
converted into a detectable signal. There are different types of detectors, the choice of which 
depends on the experimental application. The role of detector is to produce signals from incident 
ions by producing secondary electrons and their amplification or inducing the present ones 
(produced by moving charges). The preferable properties of a detector are 1. high amplification 2. 
fast time response, 3. narrow distribution of responses, 4. same response for all masses, 5.low noise, 
6. high collection efficiency, 7. large dynamic range, 8. long term stability, 9. long life, and 10. low 
cost. There are mainly two groups of ion detectors; a) point detectors: ions are temporary resolved 
and will be detected sequentially, b) array detectors: ions are spatially resolved and detected 
simultaneously [4]. 
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Tandem MS/MS - The application of tandem mass spectrometry (MS/MS) is one of the most 
used approaches for peptide sequencing [5]. In a tandem mass spectrometry experiment, the 
combination of a couple of mass analyzers is exploited in a single instrument. Due to the recent 
advances in mass spectrometry and the integration of the collision cell, new instruments are now 
suitable to perform peptide fragmentation. The fragmentation of the precursor ions in the collision 
cell will provide the respective MS/MS spectra of the precursor ions, sequence information of the 
peptides, and the information about PTMs identification and localization. The role of the precursor 
ions fragmentation in MS/MS proteomics studies is crucial for improving identification in complex 
samples and investigating PTMs. Tandem mass spectrometry provides a good platform for structure 
elucidation, selective detection of target compound, reducing interferences. 
Fragmentation techniques - To obtain information about the amino acid sequence of 
peptides from digested proteins using MS, the precursor peptide ion has to be fragmented into a 
combination of consecutively smaller fragment ions, each having lost one or more amino acids. 
Collision-induced dissociation (CID), which is the most common peptide fragmentation technique 
in MS, leads to N- and C-terminal fragment ions resulting from a cleavage of the C-N bond in the 
peptide backbone, yielding y- and b-ions [6,7]. The other relevant type of fragmentation methods in 
proteomics is electron transfer dissociation (ETD), which produces N- and C-terminal fragments of 
a backbone bond between the nitrogen and alpha carbon atom, generating c- and z-ions 
modifications, allowing their analysis and peptide sequencing [8]. The use of both ECD/ETD and 
CID increases the amount of information derived from peptide fragmentation (Fig. 1). 
 
 
Fig. 1 Scheme of peptide fragmentation proposed (Adapted from I) 
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Applicability - Different approaches can be used for the analysis of protein sequencing by 
MS/MS. The first is a bottom-up protein sequencing, in which the fragmentation of peptides derived 
from protein digestion occurs, whereas the second is the top-down sequencing, which is based on 
the direct fragmentation of intact proteins. For complex samples and large scale analysis, the 
bottom-up approach is more adopted and it is well suited for the study of peptide modifications. 
This is because analysis of short peptides is simpler, as peptides are more efficiently separated by 
techniques such as liquid chromatography and they are detected with higher mass accuracy due to 
their smaller mass. The most common enzyme used for protein digestion is trypsin, which 
specifically cleaves on the C-terminal side of Lys and Arg, providing each peptide with at least a 
basic amino acid, which increases the possibility of positive ionization. Several methods are present 
for the interpretation of tandem MS data such as de novo sequencing, in which spectra are 
investigated using amino acid masses table. The second strategy is based on database 
searching/matching with bioinformatics search engines, in which experimental fragmentation 
spectra are compared with in silico predicted peptide fragmentation of known protein sequences. 
The algorithm recognizes all of the peptides in the database with the same mass as the precursor 
ion, and it makes a comparison between predicted and observed fragments matching the most 
probable sequence. 
Bottom-up proteomics strategies - For MS analysis, proteins have to be pulled out efficiently 
from the biological sample to preserve the cellular environment of the system to be characterized. 
Residual enzymatic activities from proteases, phosphatases and other enzymes may result in 
unexpected and unnatural modifications of proteins and the cellular state. A common guideline for 
samples that do not require extensive tissue disruption is to dissolve and denature proteins by 
boiling them in a detergent such as SDS or chaotropic agents such as urea, thiourea and 
guanidinium hydrochloride. Detergent-based protocols can offer better recovery of membrane 
proteins compared to chaotropic salts- or organic solvents-based approaches. However, the majority 
of detergents are not utilizable in LC-MS and they have to be removed completely before analysis 
using purification techniques. Sample treatments mostly exploits steps to chemically protect 
cysteines by reduction, followed by irreversible alkylation, to cleave existing disulfide bonds and 
prevent them from forming again. Proteins are mainly cleaved into peptides by sequence-specific 
proteases such as trypsin. After digestion, peptide mixtures are cleaned, purified and concentrated, 
commonly in pipette-based devices filled with particular resins. A key challenge in shotgun 
proteomics remains the analysis and detection of peptides in very complex mixtures, such as whole 
cell lysates and tissues. To reach this goal, a combination of high performance liquid 
chromatography and high-resolution mass spectrometry with very high sequencing speed have 
 10 
 
proven most successful. During chromatography, peptides are fractionated in a gradient of aqueous 
to organic solvent based on their interaction with the hydrophobic stationary phase. Efficiency of 
peptide separation on the column enhances with decreasing bead size and inner column diameter 
(normally 2 mm) as well as with increasing column length (usually up to 50 cm). Eluted peptides 
are ionized by electrospray at the tip of the column and transferred into the vacuum of the mass 
spectrometer for direct analysis (Fig. 2).  
 
 
 
Fig. 2 Scheme of a typical shotgun proteomics experiment showing protein extraction, digestion, purification 
and LC-MS/MS analysis (Adapted from II) 
Q-Exactive Plus mass spectrometer - The Q-Exactive Plus consists in four main 
components: 1. Ion source 2. Intermediate storage device (C-Trap) for short pulse injection 3. HCD 
collision cell 4. Orbitrap analyzer for Fourier transform mass analysis (Fig. 3). Basically, samples 
can be introduced into the ion source and gas phase ions are transferred into the C-Trap through 
four stages of differential pumping. In the C-Trap, ions are stored and their energy dampened using 
a bath gas (nitrogen). Ions are then injected through three further stages of differential pumping 
using a lens system (Z-lens) into the Orbitrap analyzer where mass spectra are acquired via image 
current detection. The HCD cell adds a higher energy collision induced dissociation capability to 
the instrument. After the ions fragmentation into the HCD cell, its voltages are ramped up and ions 
are moved back into the C-Trap from where they are injected into the Orbitrap. In particular, this 
instrument offers advanced ion transfer guides, enhanced mass resolution and high sensitivity 
providing a perfect platform for protein analysis [9]. 
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Fig. 3  Scheme of Q-Exactive plus mass spectrometer (Adapted from III) 
 
PTMs - The term PTM describes alterations in the polypeptide chain through addition or 
removal of distinct chemical groups to amino acid residues, proteolytic processing of the protein 
termini, or the introduction of covalent crosslinks between domains of the protein. PTMs participate 
in several cellular processes such as the control of protein structure and integrity, regulation of 
metabolism and defense mechanism, cellular recognition events and morphology modifications. A 
wide range of modifications are known (more than 200) [10]. Phosphorylation and glycosylation are 
the most important and studied PTMs (Fig. 4). Correct localization and quantification are key 
elements in investigating a PTM. PTMs have been recognized by using Edman degradation, amino 
acid analysis, isotopic labeling, or immunochemistry but recently MS has been successfully applied 
in the PTM discovery. MS has shown many advantages for PTM investigation such as 1. high 
sensitivity; 2. capability to identify the site of PTM; 3. discovery of novel PTMs; 4. capability to 
pinpoint PTMs in complex mixtures of proteins; and 4. capability to quantify relative changes in 
PTM occupancy at distinct sites.  
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Fig. 4 Crosstalk between protein PTMs. Examples of positive and negative regulation of protein 
phosphorylation on different modifications ar highlighted in rounded rectangles. Interplay between 
phosphorylation and O-GlcNAcylation o specific Ser/Thr residues is also shown. (Adapted from 
IV). 
2. PHOSPHOPROTEOMICS 
Addition of a phosphate group to a protein may affect several protein properties such as folding, 
activity, capability to interact with other proteins, localization or degradation. Phosphorylation plays 
key roles in regulation of diverse cellular mechanism, including proliferation, differentiation, 
apoptosis, and cellular communication [11,12]. Alterations in reversible phosphorylation regulated 
by protein kinases/phosphatases may be the starting point of several pathological conditions 
including cancer, diabetes, chronic inflammatory and neurodegenerative diseases. Prior to MS, the 
principal techniques for identification of phosphorylation sites in proteins were 
32
P labeling [13], 
sequencing by Edman degradation [14], and site-directed mutagenesis. Despite of being very 
sensitive and specific, 
32
P labeling has common disadvantages such as the high levels of 
radioactivity involved, and a very low throughput. Cytotoxicity of the radioactive emission 
represents a limit of in vitro labeling. However, specificity of the phosphorylation is a challenge 
because of the promiscuous behavior in reactions occurring in an artificial, non-cellular context 
with abnormal concentrations of the reactions species [15]. Recently, substantial improvements in 
sample preparation, purification, enrichment, instrumentation, and bioinformatic tools, have 
facilitated the growth of the phosphoproteomics field allowing a more confident identification and 
quantification of phosphorylation sites.  
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Phosphopeptide enrichment – Immobilized metal ion affinity chromatography (IMAC) with 
different metal ions including Fe(III), Ga(III), Al(III), and Zr(III) has been employed for enriching 
phosphopeptides in large-scale proteomics experiments [16-18].  IMAC efficiency can be affected 
by several factors such as binding, washing, and elution [19]. In order to avoid the binding of non-
phosphorylated peptides, acidic conditions for loading and washing were used, eluting  
phosphopeptides using alkaline conditions [20]. Titanium dioxide (TiO2), which is also widely used 
for enriching phosphopeptides, offers high capacity and selectivity [21]. TiO2 precolumns, TiO2-
based HPLC chips, TiO2 tips were employed for purification of those peptides [22]. In order to 
increase the recovery of phosphopeptides, multiple step of incubation with the optimized amount of 
TiO2 beads were also applied [23]. Diverse strategies for the elution of bound phosphopeptides 
including ammonium bicarbonate with 50 mM ammonium phosphate (pH 10.5), ammonia solution 
(pH 10.5-11), or step gradients from pH 8.5 (100 mM triethylammonium bicarbonate) to pH 11.5 
(3% ammonium hydroxide) were also tested [24,25]. A composed method for the simultaneous 
enrichment of monophosphorylated and multiphosphorylated peptides exploiting sequentially 
elution of IMAC (SIMAC) and TiO2 was also developed [26]. Monophosphorylated peptides are 
eluted during acidic condition from IMAC and multiphosphorylated peptides by basic elution, 
leading to an increased sensitivity of detection and reduced sample complexity. Recently, polymer-
based metal ion affinity capture (PolyMAC) based on polyamidoamine dendrimers with titanium 
ions and aldehyde groups were also presented, showing high selectivity, fast chelation times, and 
high phosphopeptide recovery [27]. Fractionation of protein samples is still recommended even if 
the method exploits both IMAC and TiO2 for enriching phosphopeptides. Many chromatographic 
methods such as SCX [28], SAX [29], HILIC [30], and ERLIC [31] were used in order to increase 
the identification of phosphorylation site (Fig. 5).  
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Fig. 5 Scheme of quantitative phosphoproteomics experiments including the choice of 
chromatography, enrichment, fragmentation type, data analysis tools (Adapted from V) 
 
Phosphopeptide fragmentation – A challenge in phosphopeptide analysis is to obtain sequence 
information using the correct fragmentation strategy in MS/MS. The phosphoryl group on serine 
and threonine residues is a labile post-translational modification, especially in CID and is normally 
β-eliminated as phosphoric acid after fragmentation leading to an energetically favorable α,β-
unsaturated carbonyl group on the peptide [32]. This β-elimination from serines and threonines 
leads to increase dehydroalanine and dehydro-2-aminobuturic acid, respectively, which highlights 
the presence of a phosphorylation site. The 69 Da loss characteristic of phosphoserine-to-
dehydroalanine conversion can be used to discriminate β-eliminated phosphoserine and 
phosphothreonine. However, 98 Da neutral loss of phosphoric acid is usually the well-known 
fragmentation reaction. The neutral loss is related to several aspects including charge state (higher 
charged peptides often experience lower neutral loss), and the collision energy used during 
fragmentation step. The slowest fragmentation by using lower collision energy in ion trap 
instruments leads to generate more neutral loss of phosphoric acid compared to the faster high-
energy CID fragmentation mainly used in “tandem-in-space” instruments (quadropoles, Q-TOFs, 
etc.) [33]. This mechanism can be linked to the slowest resonant excitation (i.e. ion traps) leading to 
fragmentation through the pathways of lowest energy such as neutral loss of phosphoric acid. MS-
based phosphopeptide methods were then developed: 1. on triple quadropole instruments exploiting 
a neutral loss scanning method for the detection of the loss of H3PO4 by scanning the whole mass 
range with a fixed offset between precursor and fragment ion of 98 Da [34] and 2. on an ion trap 
instruments for serine and threonine phosphopeptide detection and sequencing by using the data-
dependent neutral-loss-triggered MS/MS/MS (MS
3
) scan [28]. In this case the loss of 98 Da from 
the precursor ion in the MS/MS spectrum causes the selection and fragmentation of the neutral loss 
ion. Due to an additional isolation and fragmentation step of the neutral loss, extra time spent and 
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loss of sensitivity are major disadvantages of this solution. Recently, MultiStage Activation (MSA), 
introduced on ion trap instruments, was shown able of removing the ion isolation round between the 
MS/MS and MS
3
 scan [35]. It provides a collisional activation in the mass-to-charge region of the 
potential neutral loss ion, while the fragments are stored in the ion trap, obtaining a spectrum which 
includes product ions from both the precursor and the neutral loss. By not exploiting extra time and 
isolation step, MSA offers shorter duty cycles and higher sensitivity compared to MS
3
. Negative ion 
mode is also applied for discovering phosphosites. In particular, m/z -79 related to PO
3-
 loss can be 
found in CID fragmentation [36,37]. In this case, development of a precursor ion scanning method, 
using a single quadrupole with in-source CID or a triple quadropole instrument in which the entire 
precursor mass range is explored detecting only mass to charge -79, are required. Relevant 
advantages are high specificity and sensitivity, but it allows only limited peptide sequence 
information. Modern instrument, which are capable of fast polarity switching between negative and 
positive ion mode, can improve identification of phosphopeptides. In the case of tyrosine-
phosphorylated peptides, the neutral loss of their phosphoryl group (a 80 Da loss of HPO3) in CID 
is rarely observed [38]. An additional indicator of the presence of these species is the finding of a 
phosphotyrosine-specific immonium ion. This ion, which results from another fragmentation N- and 
C-terminally to the phosphotyrosine, has a mass of 216.043 Da [39]. 
 
3. GLYCOPROTEOMICS 
 
A protein is glycosylated when its amide or alcohol group is covalently linked to a glycan. A N-
linked glycan is bound to the amide group of asparagines residue in an amino acid sequence motif 
of Asn-X-Ser/Thr, where X represents all amino acids except proline [40]. An O-linked 
glycosylation links the glycan to the hydroxyl group of serine or threonine. Several studies have 
explained that glycosylation, which can be mainly found on membrane and secreted proteins, 
affects diverse biological functions such as protein folding, protein turnover, and immunity. Glycan 
analysis, or glycomics, is normally focused to explore only glycan modifications in glycoproteins. 
On the other hand, glycoproteomics aims to fully study glycoproteins and glycopeptides. Glycomics 
approaches investigate glycan structures, but lose the information on localization sites because of 
the release of glycan moieties from the glycosylated proteins. N-linked glycans (Fig. 6, 7) are 
normally removed by using an amidase, such as peptide N-glycosidase F (PNGase F), which 
releases linked sugars. Due to many forms of linkage structure, an universal enzyme is not available 
for cleaving O-linked glycans. This are normally cleaved by chemical methods including 
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hydrazinolysis [41] and alkaline β-elimination [42]. Removed glycans can be analyzed with or 
without derivatization by mass spectrometry or nuclear magnetic resonance (NMR).  
 
 
 
Fig. 6 Scheme of chemical structures and masses (in hydrolysed form) of the most common 
mammalian sialic acids (i.e. Neu5Ac, Neu5Gc and Kdn) and some examples of common 
mammalian sialylated N- and O-linked glycans and determinants. The core structures for the four 
main O-linked core types (core 1–4) have been highlighted (broken lines). (Adapted from VI)  
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Glycopeptides enrichment – Enrichment steps are typically used in order to improve 
sensitivity of glycosylation sites detection due to the low abundance of glycopeptides. However, a 
several number of enrichment strategies have been introduced such as including lectin affinity 
[43,44], hydrazide coupling [45], HILIC [46,47], and boronic acid affinity [48,49]. Due to its high 
specificity, lectin-based affinity strategy is the most widely performed. Lectins are carbohydrate 
binding proteins, which can specifically bind to sugar moieties. Many different lectins can be used 
for enriching glycopeptides such as concanavalin A and wheat germ agglutinin (WGA), which 
binds respectively to mannose glycan and N-acetylglucosamine. Ulex europaeus agglutinin (UEA) 
and aleuria aurantia lectin (AAL) are lectins specific for fucose recognition. Maackia amurensis 
leukoagglutinin (MAL) and hemoagglutinin (MAH) can be used for enriching N-Acetylneuraminic 
acid [50]. 
 
Glycopeptides MS analysis – There are two different strategies for the analysis of glycopeptides 
using mass spectrometry. The first method exploits the detection of the intact glycopeptides with 
glycan; using this approach the amino acid sequence and glycosylation site can be found by the 
spectrum interpretation. This method could be ideal because glycans and peptides are detected at 
the same time, but it has some limits in large scale analysis such as glycan heterogeneity which it 
makes spectral interpretation difficult for glycopeptides, and the sugar group makes peptide 
fragmentation challenging. In addition to widely used CID method for peptide fragmentation, new 
ion dissociation methods were implemented such as infrared multiphoton dissociation (IRMPD) 
[51], electon-capture dissociation (ECD) [52], and electron-transfer disassociation (ETD) [53] in 
order to obtain more fragment ions derived from peptide backbone with no loss of the glycans. 
Different complementary dissociation approaches can be employed to fully characterize 
glycopeptide and glycan. Glycan structure details can be generated by CID fragmentation, which 
normally cleaves the glycopeptide at glycosidic bonds. In order to create more peptide backbone 
fragments for improving peptide sequence identification, ETD fragmentation can also be used. 
Another common method is to cleave glycan by using an amidase. Deglycosylated peptides are then 
analyzed by shotgun proteomics. This protocol allows only the identification of peptides which 
were glycosylated. PNGase F, which removes N-linked glycans from glycoproteins by deaminating 
asparagine to aspartic acid, results in a 1 Da mass increase. Useful targeted database can be used to 
assist N-linked glycosylation sites due to the fixed motif sequence of Asn-X-Ser/Thr increasing 
sensitivity of glycopeptides identification and reducing the false discovery rate [54]. 
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Fig. 7 Overview of LC separation and detection of sialylated N-linked glycans released from bovine 
fetuin by treating with PNGaseF. (Adapted from VII) 
 
4. QUANTITATIVE PROTEOMICS 
 
The most common proteomic approach, 2-DE, was the first tool introduced for protein 
quantification. Quantification can be easily performed by comparing the staining densities of 
proteins on different gels, obtaining a measure of relative quantification. However, 2-DE has still 
some limits such as limited resolution for a large number of proteins and entire proteomes, protein 
spots coappearance not allowing accurate quantification, incompatibility for hydrophobic and 
membrane proteins, incapability of detecting low abundant proteins. 2-DE based quantification can 
unveil only substantial differences and inaccurately estimates quantity changes. Due to these 
limitations, several strategies were developed to quantify proteomes based on the mass 
spectrometry data. MS-based quantitative data can be obtained by using stable isotope labeling or 
label-free strategies. The label-free strategy analyzes samples individually, comparing the MS ion 
intensity [55-57] of peptides or using the number of acquired spectra [58,59] matching a 
peptide/protein as an indicator for their respective amounts in a given sample. The isotope labeling 
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approach exploits the mixing of multiple samples of different biological conditions. The absolute or 
relative protein abundance can be achieved by measuring the intensities of different isotope coded 
peaks discriminated by MS. Furthermore, different methods can be mainly used to obtain 
quantitative information from mass spectrometry data such as determination of peptide precursor 
ion abundance in the MS
1
 scan and measuring the isotope coded reporter ions (which reflect peptide 
quantity) in peptide fragmentation in the MS
2
 scan (Fig. 9).   
 
 
 
Fig. 8 Overview of quantitative strategies in proteomics showing metabolic labeling as SILAC, 
chemical labeling as iTRAQ, spiked peptides and label free. (Adapted from VIII) 
 
MS
1
 based strategies – MS-based quantification methods use chemical labeling in order to 
add isotope-coded reagents to reactive groups on the side chains of amino acids or to the peptide 
termini. Isotope coded affinity tag (ICAT) [60,61], which exploits the reaction between the thiol 
side chain of cysteine and the tag, was the first chemical labeling method developed. The ICAT 
reagent is formed by three units: a biotin affinity tag, a thiol specific reactive group, and the light or 
heavy isotopes included into a linker. In this case, cysteine residues are functionalized with an 
ICAT reagent containing either eight 
1
H or eight 
2
H atoms, and the protein mixture is then purified 
by avidin affinity chromatography. Protein mixture is then digested using trypsin and analyzed by 
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LC-MS. However, ICAT technique can greatly reduce the complexity of the peptide mixture, but it 
is not suitable for comprehensive large-scale analysis because it excludes all non-cysteine-
containing peptides. Deuterium-based tag gives a shift in the retention time between light and heavy 
peptides in reversed phase (RP) chromatography, which complicates data analysis [62]. Other ICAT 
reagents include a 
13
C-labeled linker instead of deuterium [63,64]. Another labeling strategy 
exploits the use of formaldehyde in order to introduce dimethyl labels to mark the N-terminus and 
amino group of Lys residues [65,66]. In this case, the light form of formaldehyde is combined with 
cyanoborohydride to include double chemical groups of CH3 to each primary amine in a peptide. 
The medium and heavy labeled chemicals generate two sets of CHD2 and 
13
CD3, respectively, 
giving a 4 Da mass difference between three groups during MS analysis. However, dimethyl 
labeling presents a chromatographic retention time shift due to deuterium labeling as well as the 
ICAT method.  
 
MS
2
 based strategies - Isobaric tags for relative and absolute quantification (iTRAQ) [67] and 
tandem mass tags (TMT) [68] are formed by three main parts: a unique mass reporter, a cleavable 
linker as a mass balancer, and an amine-reactive group. All labeling group in a set of multiplex tags 
have the same total mass weight and these labeling parts increases co-elution of peptides during LC 
and co-isolation for fragmentation during MS/MS. Peptide mixtures obtained by different biological 
samples are then labeled with different types of the tag employing the reaction between the amine-
reactive group of the tag with the peptide N-termini and lysine residues of the peptide. During 
MS/MS the linker is fragmented, releasing the mass reporter, where the intensity evidences the 
relative abundance of the original peptide. There are several types of isobaric labeling which are 
capable of analyzing multiple labeled pools of peptides such as TMT (up to 10 samples) and 
iTRAQ (up to 8 samples) [69] in a single analysis, reducing instrument time. This strategies have 
several advantages such as not increasing the complexity of the MS1 scan and not decreasing the 
precursor signal sensitivity due to the fact that all the tags lead to the same mass increase for each 
labeled peptide. Higher-energy collisional dissociation (HCD) is typically exploited in iTRAQ and 
TMT analysis [70]. HCD offers better MS
2
 data quality because all the MS
2
 data are acquired with 
high mass accuracy, but it uses more ions and time to obtain a MS
2
 spectrum compared with that 
from normal CID. HCD-based experiment leads to lower proteome coverage. Isobaric tags has still 
also some restrictions, especially in the quantification accuracy [71,72], which is affected by co-
fragmentation of co-eluting peptides with similar m/z. During the selection of the peptide precursor, 
MS isolates the precursor in a wide m/z window, which could contain target peptide and co-eluting 
peptides. In this case, the reporter ions are obtained from a mixture leading to an unaccurate 
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quantifications. However, modified strategies were introduced to overcome this limits, such as the 
introduction of an additional MS stage to increase ion selection specificity [73,74]. In this approach, 
the most intense MS
2
 fragment ion is selected for the fragmentation, and the reporter ions generated 
during the second fragmentation are exploited for quantification. In order to not selecting non-
labeled fragments in MS
2
, Lys-C is introduced to digest proteins. After digestion, all of the peptides 
contains Lys and are labeled with isobaric tags at both termini.  
 
Label Free – Isotope labeling has still drawbacks such as the cost of labeling reagents, 
labeling efficiency, difficult detection of low abundance peptides and limitation of sample number. 
In order to overcome these drawbacks, label free can be performed instead of labeling methods. 
There are two different methods for quantifying proteins in label free such as 1. spectral counting, 
which uses the frequency of peptide identification of a particular protein as a measure of relative 
abundance or 2. ion intensity, which exploits the MS chromatographic signal intensity of peptide 
peaks belonging to a particular protein [75]. In the first case, the frequency of peptide spectral 
matches of a specific protein can be related with the amount of a protein. This method can be used 
with low and moderate mass resolution (0.1-1 Da) MS data. Moreover, the spectral counting 
employs simpler normalization and statistical analysis compared to the ion intensity method. In 
order to calculate the protein abundance, protein abundance index (PAI), which is the number of 
identified peptides divided by the number of observable peptides for each protein, can be used [76]. 
PAI can be converted into emPAI (exponentially modified), which reflects protein abundance in a 
sample [77]. This parameter can be employed for searching databases and search engines such as 
Mascot and SEQUEST. However, peptides with different physicochemical properties can produce 
bias in MS results. In order to overcome this disadvantage, a modified spectral counting method, 
called the absolute protein expression (APEX), was proposed for measuring the protein 
concentration per cell, based on the number of observed peptides for a protein and the probability of 
MS detection of peptides [78]. The ion intensity method exploits the integration of all 
chromatographic peak areas of a given protein, the area under the curve (AUC) being related to the 
concentration of peptides in the range of 10 fmol to 100 pmol. This AUC-based protein 
quantification method, which is called “the ion count”, is performed by measuring the ion 
abundance at specific retention times for given ionized peptides. It can be useful for quantification 
within the given detection limits of the instrument [79]. This strategy can be affected by several 
factors such as peptide co-elution, multiple signals for the same peptide due to technical or 
biological variation in retention time, MS speed and sensitivity, and background noise due to 
chemical interference. In order to improve these drawbacks, computational methods that include 
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mass accuracy and alignment of retention times of peptides across various sets, background noise, 
and peak abundance normalization have been developed [80]. A combination of both spectral 
counting- and ion intensity-based label-free quantification further improved accuracy [81]. 
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ABSTRACT 
Platelet-derived MPs (PMPs) are a heterogeneous population of microvesicles released from 
platelets upon activation and apoptosis. Different platelet activations may affect PMP protein 
profiles and roles in intercellular communication. Here, we performed a quantitative proteomics 
study to characterize the protein content of PMPs generated by four differentially activated platelet 
samples. We selected known physiological agonists for platelet activation such as ADP, thrombin 
and collagen. Thrombin, which is mostly used to generate PMPs in vitro, was set as control. 
Platelets were activated by following a known agonist strength scale in which ADP was the weakest 
activation and thrombin and collagen stimulations were the strongest ones. Our proteomics analysis 
allowed the quantification of 3383 proteins, of which 428 membrane and 131 soluble proteins were 
found as significantly different in at least one of the analyzed conditions. Activation with stronger 
agonists led to the enrichment of proteins related to platelet activation in PMPs. In addition, 
proteins involved in platelet degranulation and proteins from the electron transport chain were less 
abundant in PMPs when stronger activation was used. Collectively, our data describe the most 
detailed characterization of PMPs after platelet physiological activation. Furthermore, we show that 
PMP protein content is highly dependent on the type of physiological agonist involved in platelet 
stimulation. 
1. INTRODUCTION 
Platelet-derived microparticles, first identified by Wolf in 1967 as “platelet dust”[1], are 
submicrometer wide (0.1-1µm) membrane vesicles, resulting from the reorganization of the platelet 
membrane in response to several conditions such as platelet activation and apoptosis [2]. In addition 
to microparticles, platelets are known to generate exosomes from the exocytosis of multivesicular 
bodies (MVBs) and alpha-granules [3]. MPs from different cell types can be found in human 
plasma, and PMPs represent the major population of circulating MPs [4,5]. It was recently shown 
that megakaryocytes, progenitor of platelets, also release MPs [6]. PMPs are crucial for several 
physiological functions, including regulation of hemostasis, and their importance has been 
demonstrated by the bleeding disposition with a diminished formation of PMPs in patients with 
Castaman disease [7]. Changes in the MP population have been detected in many pathological 
disorders such as cardiovascular (e.g. coronary heart disease and acute coronary syndrome [8]), 
infections (e.g. sepsis [9]), autoimmune diseases (e.g. multiple sclerosis [10] and rheumatoid 
arthritis [11]) and cancer (e.g. gastric and breast cancer [12,13]). However, little information is 
available about the mechanism of MP formation, in particular regarding the biological process that 
controls the distribution of proteins between the MPs that are being released and the remaining 
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platelet [14]. During activation and apoptosis, signalling starts from specific receptors followed by 
common vesiculation processes such as Ca
2+
 entry, cytoskeletal remodelling, calpain/caspase 
activity and mitochondrial depolarization [15].  However, PMP formation-related events, such as 
phosphatidylserine (PS) exposure and precoagulant activity, are different in the case of activation 
and apoptosis. [16]. Platelet activation can be performed by both biochemical and mechanical 
stimuli. Disruption of the contact between platelet glycoprotein Ib beta chain and cytoskeleton is a 
key event in mechanical platelet stimulation [17] as well as integrin αIIb-β3 receptor activity in 
biochemical activation [18]. In particular, platelet activation promoted by biochemical agonist is 
also called sustained calcium induced platelet morphology (SCIP), due to the role of intracellular 
Ca
2+
 concentration for the MP generation. 
Currently, the most common approaches to inspect MPs are flow cytometry, imaging by 
microscopy, ELISA and mass spectrometry-based proteomics [19]. The high mass accuracy, high 
speed and the possibility to perform high throughput analyses have made MS-based proteomics the 
preferred strategy to analyze complex protein mixtures [20-22]. This is also due to recent 
developments in the proteomics workflow, including sample preparation, liquid chromatography 
and bioinformatics tools for data processing. Recently, a shotgun proteomics approach was 
successfully applied to investigate the proteomic profile of ADP induced MPs [23]. By using gel 
filtration chromatography, Dean et al. separated PMPs into four size classes ranging from greater 
than 500 nm to approximately 100 nm and analyzed each fraction by LC-MS/MS showing that 
PMPs size classes contain proteins of different subcellular origin with mitochondrial proteins highly 
represented in the largest MPs and α-granule proteins predominating in the smallest fraction [24]. 
By using flow cytometry analysis, Pérez-Pujol et al. revealed that the PMP composition is highly 
dependent on the activation mechanism, showing substantial differences between thrombin receptor 
activated peptide (TRAP) and calcium ionophore-stimulated MPs [25]. Comparative proteomics 
was also performed to characterize PMPs generated in response to biomechanical (high shear) and 
biochemical (thrombin) stimulations, revealing 26 differentially expressed proteins, 21 of which 
were part of a common network related to cell assembly, organization and cell morphology [26]. 
Recently, Aatonen et al. studied the protein content of extracellular vesicles generated from 
differentially activated platelet samples using both physiological and not-physiological agonist 
leading the identification of only 267 proteins in the MPs [27]. However, a comprehensive and 
detailed comparison between PMPs protein content, composition and abundance after platelet 
stimulation with different physiological agonists has not yet been performed.  
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In this work, we used MS-based quantitative proteomics to investigate changes in protein content 
and abundance in PMPs generated by differentially activated platelets. Two studies investigated the 
physiological strength of different agonists for platelet activation; i.e. C5b-9 > thrombin and 
collagen > thrombin > collagen > ADP > epinephrine [27,28]. Therefore, we selected for platelet 
stimulation ADP, collagen, thrombin and collagen/thrombin, where thrombin was used as control 
due to its frequent use to generate MPs in vitro [26]. Moreover, thrombin plays a key role in 
myocardial infarction [29], ischemic stroke [30] and peripheral arterial vascular disease [31]. 
Understanding how platelet interacts with thrombin has raised great interest also for the 
development of anti-platelet drugs [32]. In addition, we tested the action of thrombin and collagen 
together in order to study a stronger platelet activation effect as compared to individual agonists 
[33]. Results highlighted a sustained increase of cytosolic Ca
2+
 concentration during thrombin and 
collagen co-stimulation [34]. After clustering and protein-protein interaction studies of the 
quantified proteins we found biological links between agonist strength and PMP composition such 
as platelet activation and degranulation proteins, energy related proteins important for the electron 
transport chain, glycolysis, pentose phosphate pathway and the proteasome. 
2. MATERIALS AND METHODS 
All chemicals were purchased from Sigma (St. Louis, MO, USA) unless otherwise stated. Ultrapure 
water was from an ELGA Purelab Ultra water system (Bucks, U.K.).  
Platelet isolation and MP generation – PMPs were obtained from fresh apheresis platelets 
provided by three healthy volunteers in accordance with the guidelines of the University of 
Southern Denmark (SDU) and the Odense University Hospital (OUH). Platelets (7x10
7
 cells) were 
isolated and activated to obtain PMPs as previously described with minor modifications [14,23]. 
Briefly, platelets were pelleted by centrifugation at 700 x g for 20 min at 20°C. The pellet was 
washed twice with 137 mmol l
-1
 NaCl, 2.6 mmol l
-1
 KCl, 1 mmol l
-1
 MgCl2, 11.9 mmol l
-1
 
NaHCO3, 5.6 mmol l
-1
 D-Glucose and 1 mmol l
-1
 EDTA (Buffer A, pH = 6.5), and resuspended in 
buffer A without EDTA (Buffer B, pH = 6). Platelet suspensions were divided in four aliquots of 5 
ml each and stimulated in presence of a) 10 mol l-1 ADP [23], b) 1 U ml-1 thrombin, c) 20 µg ml-1 
collagen and d) 1 U ml
-1
 thrombin plus 20 g ml-1 collagen. The mixtures were incubated for 10 
min at 37°C for ADP stimulation and for 30 min at 37°C for the other treatments. Finally, the 
activations were stopped by adding 2.5 mmol l
-1
 final concentration of EDTA or 2 mmol l
-1
 EGTA 
in the case of the ADP stimulation. Activated platelets were removed by centrifugation at 700 x g 
and 1,000 x g for 20 min at 20°C and the supernatants containing platelet derived MPs suspensions 
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were collected. Platelet derived MPs were then pelleted by centrifugation at 130,000 x g for 60 min 
at 4°C.  
MP lysis and protein digestion – PMPs pellets were resuspended in ice-cold Na2CO3 buffer 
(0.1 M, pH = 11) containing protease inhibitor (Roche complete EDTA free, Meylan, France), 
PhosSTOP phosphatase inhibitor cocktail (Roche, Meylan, France) and 10 mM sodium pervanadate 
on ice. The suspension was tip probe sonicated for 20 sec (amplitude = 50%) twice and incubated 
on ice for 60 min to lyse the microparticles. The lysate was then centrifuged at 100,000 x g for 90 
min at 4°C to enrich membrane proteins (pellet). The supernatant (soluble proteins) was 
concentrated using 10 kDa cutoff Amicon ultra centrifugal filters units (Millipore, Billerica, 
MA,USA), whereas membrane fraction was redissolved directly in urea 6 M, thiourea 2 M and tip 
probe sonicated for 20 sec (amplitude = 20%). Both fractions were reduced in 10 mM dithiothreitol 
(DTT) for 30 min and then alkylated in 20 mM iodoacetamide (IAA) for 30 min at room 
temperature in the dark. Lysyl Endopeptidase C (Wako, Osaka, Japan) was added for 3 h (1:100 
w/w) and then the samples were diluted  8 times with 50 mM triethylammonia bicarbonate (TEAB, 
pH = 8). Trypsin was added at a ratio of 1:50 (w/w) and left overnight at 37°C to digest. Following 
incubation, samples were acidified with formic acid (2% final concentration) and centrifuged at 
14,000 x g for 10 min to stop trypsin digestion and precipitate insoluble material such as lipids. The 
supernatant was purified using in-house packed staged tips with Poros R2 and Oligo R3 reversed 
phase resins (Applied Biosystem, Foster City, CA, USA). Briefly, a small plug of C18 material (3M 
Empore) was inserted in the constricted end of a P200 tips, followed by packing of the stage tip 
with the resin (resuspended in 100% ACN) by applying gentle air pressure. The acidified sample 
was loaded onto the micro-column, after equilibration of the column with 0.1% trifluoroacetic acid 
(TFA), washed twice with 0.1% TFA and peptides were eluted with 60% ACN/0.1% TFA. A small 
amount of purified peptides (6 µl) was dried down and subjected to amino acid composition 
analysis to determine the concentration, while the remaining sample was lyophilized prior to 
iTRAQ labeling.  
iTRAQ labeling and peptide fractionation – Equal amount of peptides from each condition 
were iTRAQ 4-plex
TM
 labeled according to manufacturer’s instructions (Applied Biosystem, Foster 
City, CA, USA). Labeled peptides were combined in 1:1:1:1 proportion based on the quantification 
achieved from the amino acid composition analysis and MALDI-MS/MS analysis (Bruker 
Daltonics, Billerica, CA, USA, in lift mode). The samples were labeled as follow: ADP, iTRAQ-
114; thrombin (control), iTRAQ-115; collagen, iTRAQ-116; thrombin plus collagen, iTRAQ-117. 
All peptide samples were fractionated by using hydrophilic interaction chromatography (HILIC) on 
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an Agilent 1200 HPLC system [35]. Samples were loaded onto a 450 µm OD x 320 µm ID x 17 cm 
micro-capillary column packed with TSK-gel Amide 80 (3 µm, Tosoh Bioscience, Japan). Peptides 
were resuspended in solvent B (90% ACN/0.1% TFA) and eluted over a gradient of 100% to 60% 
solvent B (solvent A = 0.1% TFA) over 35 min, followed by 60% to 0% over 7 min at a flow rate of 
6 µl/min. HILIC fractions were combined into eleven samples and lyophilized. 
Reversed-phase nanoLC-ESI-MS/MS – Dried fractions were resuspended in 0.1% formic 
acid (FA) (solvent A) and loaded onto an Ultimate 3000 RSLC nanoLC system (Thermo Fisher 
Scientific) coupled to a Q-Exactive Plus mass spectrometer (Thermo Fisher Scientific, Bremen, 
Germany). The peptides were loaded onto a two-column setup employing an Acclaim PepMap 100 
precolumn (100 µm x 2 cm, C18, 5 µm, 100A, nanoViper) and a 20 cm fused silica capillary column 
(75 µm ID) packed with Reprosil – Pur C18 AQ 3 µm reversed-phase material (Dr. Maisch, 
Ammerbuch-Entrigen, Germany). The HPLC gradient was 1-35% solvent B (95% ACN/0.1% FA) 
in 60 min at a flow-rate of 250 nl/min. The mass spectrometer was operated in positive mode with a 
data dependent acquisition method (Top N, N = 12). A falcon tube with 5% v/v ammonia solution 
was placed below the needle tip of the chromatographic column, located next to the orifice of the 
mass spectrometer to decrease the charge state of the ions and increase the HCD fragmentation [36]. 
Briefly, MS scans (400-1400 m/z) were recorded at a resolution of 70,000. The automatic gain 
control (AGC) target for MS acquisitions was set to 1 × 10
6
 with a maximum ion injection time of 
120 msec. Microscans were set to 1 for both the MS and MS/MS. Dynamic exclusion was set to 15 
sec. Singly charged species were rejected. Peptides of two and higher charges were fragmented into 
the HCD collision cell with a normalized collision energy (NCE) set to 32. Subsequent MS/MS 
scans with a target value of 2 × 10
4
 ions were collected with a maximum injection time of 100 msec 
and a resolution of 17,500. All MS and MS/MS spectra were acquired in profile mode. 
Data Analysis – The Proteome Discoverer software (v.1.4.0.288, Thermo Fisher Scientific) 
was used to perform database searching and peptide/protein relative quantification. MS/MS spectra 
were searched using MASCOT (v2.3, Matrix Science, London, UK) and Sequest HT (Thermo 
Fisher Scientific) as database searching engines with a Swiss-Prot v.3.53 human database (20, 243 
entries) and the Uniprot human reference database (updated April 2014). Methionine oxidation, 
peptide N-terminal iTRAQ labeling and lysine iTRAQ labeling were set as variable modifications, 
while cysteine carbamidomethylation was set as fixed modification. Precursor mass tolerance was 
set to 10 ppm and MS/MS tolerance to 0.05 Da. Trypsin was selected as digestion enzyme, and up 
to two missed cleavages were allowed. Data were filtered to a 1% false discovery rate using 
Proteome Discoverer’s Percolator function [37]. Protein iTRAQ ratios were log2 transformed and 
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normalized for the average to compensate for unequal amounts of digested and labeled protein 
samples in the sample mixture. One tail heteroscedastic Student’s t-test (p-value < 5%) was used to 
assess statistical differences in protein amount between conditions. Annotation and classification of 
the identified proteins were performed by using Protein Center (Thermo Fischer Scientific). 
Clustering analysis was performed by using Perseus (v. 1.5.0.15, tool of MaxQuant package). 
Literature mining of protein-protein interactions was performed using STRING (v. 9.1) in action 
view at high settings (0.7) [38]. Membrane protein which did not have clear sequence signatures 
that characterize them as membrane proteins, were subjected to KohGPI analysis 
(http://gpi.unibe.ch/) in order to identify possible GPI-anchor signals. 
3. RESULTS 
In this study we investigated the composition of PMPs by pursuing a comprehensive comparative 
study of the proteome of such particles produced by differentially activated platelets from healthy 
subjects. Thrombin, which is mostly used to generate PMPs in vitro, was chosen as control [26]. 
Activation was also performed by using ADP, collagen and thrombin plus collagen, as all are 
known to play a role in nature as physiological agonists. PMPs were first generated from platelet, 
lysed, and partitioned into membrane and soluble fractions by treatment with Na2CO3, which 
linearizes membranes and releases loosely bound proteins from membrane [39] and subsequent 
ultracentrafugation. After trypsin digestion and purification, peptides from each condition were 
labeled with iTRAQ and merged to reduce variability of the analysis for quantitative proteomics. 
Samples were mixed, fractionated by hydrophilic interaction liquid chromatography (HILIC) and 
analyzed by nano liquid chromatography (nLC)-MS/MS (Fig. 1). All experiments were performed 
in biological triplicates. 
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Fig. 1 Experimental scheme for the quantitative analysis of platelet-derived microparticles proteome 
by using different agonist stimulations.  
Protein identification and comparison analysis – Using the nLC-MS/MS analysis we 
identified a total of 2380 proteins in the membrane fraction, 1476 of which showed a 
transmembrane (TM) domain or a signal peptide characteristic for membrane proteins. A total of 
1109 proteins were found in all three biological replicates (46.6%). On the other hand, 2399 
proteins were identified in the soluble fraction, 1109 (46.2%) of which were found in all three 
biological replicates. Such data evidenced the high reproducibility between biological replicates. 
After removing redundancy, a total of 3383 proteins were identified in our study, 984 were found 
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only in the membrane fraction and 1003 were found only in the soluble fraction (Fig. 2A). The large 
number of proteins identified in both fractions indicated that the purification of the membrane 
fraction from the soluble has still its limitations most likely due to large protein complex formation. 
However, by determining the presence of TM domains and signal peptides we could determine 
which proteins contain amino acid sequence signature that characterize them as membrane 
associated with high confidence. In addition, by using KohGPI on proteins which did not show 
clear sequence signatures that characterize them as membrane proteins (904 proteins), we found 5 
proteinshaving both C- and N-terminal signal sequences (GPI-anchored). By performing iTRAQ-
based relative quantification, we determined the ratio of the identified proteins in PMPs in the 
analyzed conditions. In the membrane fraction a total of 350 proteins (243 of which showed TM 
domain or signal peptide) were found to be significantly different in terms of relative abundance in 
the ADP induced MPs as compared to the control, which was thrombin stimulation. One hundred 
and sixty eight proteins (113 of which showed a TM domain or a signal peptide) were significantly 
different in collagen induced activation and 147 proteins (98 of which showed a TM domain or a 
signal peptide) in thrombin and collagen co-stimulated MPs (Fig. 2B). For the soluble fraction, 40 
proteins were identified to be significantly different in ADP stimulated microparticles, 97 proteins 
in collagen induced activation and 49 proteins in thrombin and collagen co-stimulated MPs (Fig. 
2C).  
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Fig. 2 A) Venn diagrams showing the overlaps between all of the identified proteins in this study. 
B) Overlaps between significantly different proteins in the membrane and C) the soluble fractions.  
 
Gene ontology analysis of proteins with significantly different abundance between 
treatments – We next characterized the gene ontology of differentially expressed proteins during 
different stimulations. Regarding the membrane fractions (especially in ADP induced MPs), 
biological processes analysis showed that most of the proteins detected were involved in cell 
communication, metabolic process, response to stimulus and transport (Fig. 3A). Molecular 
functions analysis underlined that the majority of proteins played roles in catalytic activity and 
protein binding (Fig. 3B). Regarding all of the soluble fractions (especially in collagen induced 
MPs), biological processes analysis highlighted that proteins were mostly implicated in cell 
communication, cell organization and biogenesis, metabolic process, regulation of biological 
processes, development and response to stimulus (Fig. 3C). Molecular functions analysis displayed 
 40 
 
(especially in collagen induced MPs) that proteins are involved in catalytic activity and protein 
binding (Fig. 3D). 
 
Fig. 3 Gene ontology graphs categorizing proteins for A) biological processes in the membrane 
fraction or C) soluble fraction, and B) molecular functions in the membrane fraction or D) soluble 
fraction. Blue, red and green bars indicate protein groups found as significantly more or less 
abundant in ADP, collagen, thrombin and collagen fractions as compared to control.    
Next, we performed cluster analysis, considering the relative abundance of a protein in the three 
treatments as compared to control. We divided the trends of protein abundance into six clusters for 
the membrane and six for the soluble fraction. Proteins belonging to the same cluster were subjected 
to STRING analysis to perform literature mining of protein-protein interactions and protein 
networks. Regarding the membrane fraction, two major clusters were found to be associated to 
platelet mediated processes. A first cluster (Fig. 4A), containing 134 membrane proteins mostly 
abundant in ADP induced PMPs (Fig. 4B), grouped two different networks related to platelet 
degranulation and the electron transport chain (Fig. 4C). A second cluster, including 262 proteins 
that were mostly abundant in thrombin and collagen co-stimulated PMPs, was enriched in proteins 
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associated to regulation of the actin cytoskeleton, proteasome and glycolysis/pentose phosphate 
pathway (Fig. 5). Interestingly, in the soluble fraction one cluster (Fig. 6A), which contains 78 
proteins that were mostly abundant in ADP induced PMPs (Fig. 6B), was found to be related to 
platelet degranulation (Fig. 6C). In particular, we found a general high enrichment in all treatments 
of proteins involved in cell communication, which suggests the role of PMPs in the intercellular 
communication network [28].  
4. DISCUSSION 
In this work, we carried out a proteomics study of PMPs obtained by differentially activated platelet 
samples. Apheresis platelets, which ensure very low RBCs and leukocytes contaminations, were 
used for microparticles generation. Activations were performed using relevant platelet physiological 
agonists following published procedures with minor modifications [14,23]. An additional 
centrifugation step (1000 x g) was introduced to further purify microparticles from platelets. 
However, despite the supernatant was formed mainly by PMPs, we cannot exclude possible 
exosome contaminations into our samples. The treatment with Na2CO3 was applied to fractionate 
soluble and membrane proteins, and thus increase sensitivity of the analysis. However, in the 
membrane fraction we found about 38% of proteins which did not have clear sequence signatures 
that characterize them as membrane proteins. HILIC fractionation also revealed as an efficient 
method to decrease sample complexity and increase sensitivity of the analysis (Fig. 7).  
Platelet activation is known to be driven by the rearrangement of the actin cytoskeleton [40]. Our 
analysis revealed significant changes in proteins involved in this function in PMPs. Specifically, for 
these proteins we observed a decrease in the ADP and collagen induced MPs and an increase in the 
thrombin and collagen co-stimulated MPs. This also suggested a direct link between proteins related 
to platelet activation and physiological agonist strength. Agonists such as ADP or collagen alone 
were found to be weaker than thrombin and thrombin/collagen together in activating platelet, and 
proteins involved in cytoskeleton organization were found to be less abundant when the weakest 
activators were used. CD9 antigen is the third most abundant protein on the platelet surface and it is 
involved in the platelet activation mechanism [41] together with integrin αIIbβ3 [18]. The last two 
platelet integrin’s were both identified to be less abundant in ADP induced activation than control. 
Interestingly, CD9 antigen, which was shown to be associated with integrin αIIb-β3 [42], was found 
to be increased in the same induced activation. Talin-1 was less abundant in the ADP induced 
stimulation and more abundant in thrombin and collagen co-stimulation; this protein was previously 
shown to be required for inside-out activation of platelet integrin’s in hemostasis and thrombosis 
[43]. Actin-related protein 3, also found to be less abundant in ADP induced activation, was 
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previously shown to be involved in platelet activation by regulating actin cytoskeleton assembly 
[44]. We also observed lower amounts of profilin-1 in PMPs after ADP induced stimulation, which 
is a critical protein involved in building actin networks by promoting actin related protein 3 
activation [45]. Finally, we found vinculin decreased in ADP induced activation, which was 
recently found to be a possible biomarker of atherosclerotic disease [46], in which platelet 
activation has a central role [47]. 
 
 
Fig. 4 A) Heat map representing log2 fold changes of the quantitative data (green-lowest abundance 
and red-highest abundance). B) Trends of the abundance of a specific cluster and C) protein-protein 
interaction analysis of the same cluster highlighting protein networks involved in electron transport 
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chain (blue) and platelet degranulation (red). Thicker, blue and black lines indicate more confident, 
binding and reaction associations, respectively. 
 
Fig. 5 Protein-protein interaction analysis of a membrane fraction cluster showing three different 
networks of protein related to regulation of actin cytoskeleton (black), proteasome (purple) and 
glycolysis/pentose phosphate pathway (brown). Thicker, blue and black lines indicate respectively 
more confident, binding and reaction associations. 
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Fig. 6 A) Heat map representing log2 fold changes of the quantitative data (green-lowest abundance 
and red-highest abundance). B) Trends of the abundance of a specific cluster and C) protein-protein 
interaction analysis of the same cluster highlighting proteins network involved in platelet 
degranulation (green). Thicker, blue and black lines indicate more confident, binding and reaction 
associations, respectively. 
As mentioned above, in the same cluster of proteins identified to be less abundant in ADP and 
collagen induced PMPs and more abundant in thrombin and collagen co-stimulated PMPs, a small 
subgroup of proteins involved in the glycolysis and pentose phosphate pathway was found. These 
pathways, together with oxidative phosphorylation, are important for platelet energy metabolism 
[48]. Interestingly, proteins related to ADP activation, which leads these bio-energetic processes 
together with ATP, were found to be decreased.  
 
A B 
C 
Platelet 
degranulation 
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Fig 7. HILIC chromatograms showing the fractionation of the membrane and the soluble proteins 
respectively in the (A) first and in the (B) second replicates. 
 
These results suggest a double role of ADP in platelets as agonist by triggering the activation 
process and as energetic molecule by probably inducing compensatory mechanisms, which affect 
the abundance of ATP-related proteins. Glyceraldehyde-3-phosphate dehydrogenase, decreased in 
ADP induced activation, was shown to be required for the transport of nitric oxide in platelets [49]. 
ATP-dependent 6-phosphofructokinase platelet type, also found to be less abundant in ADP 
induced PMPs, was shown to plays a critical role in cell proliferation in breast cancer cells [50]. A 
small group of proteins, included into the large protein complex proteasome, was also found to be 
changed. As shown, these proteins belong to a cluster which was identified to be decreased in ADP 
and collagen induced PMPs and increased in thrombin and collagen co-stimulated PMPs, thereby 
associated with activation strength. It is known that the activity of the proteasome in protein 
degradation is an ATP-dependent process [51]. Moreover, it was shown that stimulated platelet 
functions and thrombosis can be supported by proteasome proteolysis [52]. In this group we also 
found the proteasome subunit alpha type-3, which was shown to regulate thromboxane A2 receptor 
by inducing a multitude of downstream signaling events in platelets related to platelet shape change, 
aggregation and secretion [53,54]. We also found a group of proteins involved in the electron 
transport chain (Fig. 4C) more abundant in PMPs after ADP stimulation. Once again, ADP may 
activate platelet as an agonist and it may induce compensatory mechanisms by affecting the 
expression of ATP-related proteins such as ATP synthase subunit gamma mitochondrial and ATP 
A B 
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synthase subunit d, mitochondrial, found to be increased in ADP induced activation, which provide 
energy to the cells through the synthesis of ATP in the mitochondria. Active components of 
Complex I, involved in respiratory electron transport chain such as NADH dehydrogenase 1 subunit 
C2, NADH dehydrogenase iron-sulfur protein 8 mitochondrial, acyl carrier protein mitochondrial, 
NADH dehydrogenase 1 alpha subcomplex subunit 7 were found to be more abundant in ADP 
induced PMPs. Complex I inhibition, through accumulated damage caused by reactive oxygen and 
nitrogen species and by the binding of environmental toxins, plays a role in the development of 
neurodegenerative disorders such as Parkinson's [55], Alzheimer's and Huntington's diseases [56]. 
Taken together, these results suggest that activation could affect platelet mitochondria related 
processes such as the respiratory chain. 
Finally, we investigated proteins involved in platelet degranulation. We grouped them into two 
different clusters, in which they were found to be increased in PMPs after ADP stimulation. These 
clusters were identified in both membrane and soluble fraction (Fig.4C, 5C). Platelets can work as 
an exocytotic cell releasing different types of useful molecules for the sites of vascular injury or for 
the storage such as alpha-granules, dense-granules and lysosomes [57]. Degranulation, which is also 
induced by physiological agonist through activation, was shown to be related to several pathologies 
[58,59]. Taken together, these results suggest a connection between proteins related to platelet 
degranulation and agonist strength. ADP, which was shown to induce partial degranulation [60], 
was considered to be weaker in activating platelet compared to the other agonists. Interestingly, we 
found proteins involved in degranulation more abundant in PMPs after ADP stimulation compared 
with thrombin stimulation. Moreover, we found SPARC, highly abundant in ADP induced 
activation, which is known to be involved in wound healing by facilitating the angiogenesis [61] 
and in acute coronary syndrome, which is a platelet activation related disease [62]. Interestingly, 
thrombospondin-1 and multimerin-1 were found to be increased during all of the activation 
performed in this study as compared to the control. In combination with von Willebrand factor, also 
found in our study, thrombospondin-1 was shown to mediate, platelet hemostasis by affecting the 
platelet adhesion to the sites of vascular injury [63]. Multimerin-1 was shown to promote platelet 
adhesion at sites of vascular injury as well by acting as adhesive ligand [64].  
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5. CONCLUSIONS 
In conclusion, our proteomics approach revealed that the protein composition in PMPs was directly 
related to the agonist used for platelet stimulation. Platelet activation proteins were more abundant 
when using stronger agonists, while platelet degranulation proteins were lower. We observed a 
difference in expression of ATP-related proteins during MPs generation in ADP induced activation, 
suggesting the presence of compensatory mechanisms related to energy depletion. Collectively, our 
MS-based quantitative study provided an overview of the PMP proteome, which can be of high 
interest to reveal biological insights about platelet response to stimuli. 
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6. APPENDIX  
Table 1. Dataset of significantly changed membrane proteins after cluster analysis 
ADP Collagen 
Thr. & 
Collagen Cluster Accession 
0.2909437 -1.113208 0.8222646 Cluster 1 Q9UBM7 
0.2763678 -1.109119 0.8327515 Cluster 1 Q562R1 
0.2891396 -1.112712 0.8235721 Cluster 1 Q92619 
0.2966776 -1.114769 0.8180912 Cluster 1 P21964 
0.3123612 -1.118897 0.8065358 Cluster 1 Q9UNL2 
0.3428897 -1.126338 0.7834478 Cluster 1 Q9UIA9 
0.3116312 -1.118709 0.8070782 Cluster 1 P63000 
0.3291564 -1.123088 0.7939321 Cluster 1 H7BZJ3 
0.2254327 -1.093474 0.868041 Cluster 1 Q96DT5 
0.2137515 -1.089593 0.8758413 Cluster 1 P63098 
0.2150954 -1.090045 0.8749493 Cluster 1 M0R1L7 
0.1979361 -1.084167 0.8862304 Cluster 1 Q16698 
0.14688 -1.065317 0.9184368 Cluster 1 P00352 
0.1449199 -1.064553 0.9196332 Cluster 1 P30101 
0.1264514 -1.057211 0.93076 Cluster 1 Q99747 
0.1328571 -1.059787 0.9269303 Cluster 1 Q9H8H3 
0.1002016 -1.046329 0.946127 Cluster 1 O95169 
0.114131 -1.052169 0.9380378 Cluster 1 P61586 
-0.051087 -0.973477 1.024565 Cluster 1 Q93009 
-0.036851 -0.981065 1.017916 Cluster 1 P17612 
-0.015914 -0.991948 1.007862 Cluster 1 P35613 
-0.068312 -0.964092 1.032405 Cluster 1 P50453 
0.0036196 -1.001805 0.9981853 Cluster 1 Q15642 
0.0534325 -1.025645 0.9722126 Cluster 1 O76074 
-0.174239 -0.90143 1.075669 Cluster 1 O95858 
-0.193375 -0.88919 1.082565 Cluster 1 P35813 
-0.14996 -0.916551 1.066511 Cluster 1 P11021 
-0.120405 -0.934346 1.054751 Cluster 1 P27797 
-0.133262 -0.926687 1.059949 Cluster 1 P62258 
-0.355698 -0.773524 1.129221 Cluster 1 P07237 
-0.350508 -0.777562 1.12807 Cluster 1 Q86Y82 
-0.36531 -0.765982 1.131292 Cluster 1 P49247 
-0.362709 -0.768031 1.130739 Cluster 1 O60506 
-0.372605 -0.760204 1.132809 Cluster 1 Q9BS40 
-0.373027 -0.759868 1.132895 Cluster 1 Q9HBH0 
-0.293642 -0.820304 1.113946 Cluster 1 P49368 
-0.293661 -0.82029 1.113951 Cluster 1 P25787 
-0.319711 -0.80105 1.120761 Cluster 1 P18859 
-0.308277 -0.809565 1.117842 Cluster 1 P22314 
-0.310915 -0.80761 1.118525 Cluster 1 P11171 
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-0.304986 -0.811996 1.116981 Cluster 1 P14618 
-0.312007 -0.806799 1.118806 Cluster 1 Q9UDY2 
-0.261543 -0.843239 1.104782 Cluster 1 P08575 
-0.234511 -0.861904 1.096415 Cluster 1 Q9C0I1 
-0.456046 -0.690681 1.146727 Cluster 1 P22061 
-0.463947 -0.683758 1.147705 Cluster 1 P15170 
-0.465071 -0.682769 1.14784 Cluster 1 P30740 
-0.46715 -0.680935 1.148085 Cluster 1 Q9Y2A7 
-0.48867 -0.661701 1.150371 Cluster 1 P00441 
-0.47863 -0.670731 1.149362 Cluster 1 Q8N5J2 
-0.481729 -0.667955 1.149684 Cluster 1 H3BPE1 
-0.478201 -0.671116 1.149316 Cluster 1 P12318 
-0.419862 -0.72162 1.141482 Cluster 1 P61088 
-0.419145 -0.722221 1.141365 Cluster 1 O43707 
-0.418814 -0.722498 1.141312 Cluster 1 Q05655 
-0.416088 -0.724776 1.140864 Cluster 1 O94925 
-0.694673 -0.451458 1.146131 Cluster 1 P61106 
-0.683078 -0.46472 1.147798 Cluster 1 P50552 
-0.686042 -0.461348 1.14739 Cluster 1 Q7L5N1 
-0.687818 -0.459322 1.14714 Cluster 1 P09211 
-0.686878 -0.460395 1.147273 Cluster 1 P47755 
-0.659351 -0.491264 1.150615 Cluster 1 Q99832 
-0.653953 -0.497195 1.151148 Cluster 1 P52907 
-0.65596 -0.494995 1.150955 Cluster 1 P58546 
-0.666774 -0.483044 1.149818 Cluster 1 Q8N9N7 
-0.666194 -0.48369 1.149883 Cluster 1 P53396 
-0.613427 -0.540506 1.153933 Cluster 1 O00139 
-0.615427 -0.538417 1.153844 Cluster 1 P54920 
-0.612643 -0.541323 1.153966 Cluster 1 P46109 
-0.620472 -0.533127 1.153599 Cluster 1 Q9BXS5 
-0.606616 -0.547582 1.154197 Cluster 1 P40306 
-0.60372 -0.550573 1.154293 Cluster 1 P28072 
-0.570166 -0.584505 1.154671 Cluster 1 Q9BUL8 
-0.570322 -0.58435 1.154672 Cluster 1 P62993 
-0.565137 -0.589478 1.154615 Cluster 1 P23528 
-0.584597 -0.570073 1.15467 Cluster 1 P01023 
-0.58382 -0.570856 1.154676 Cluster 1 Q14554 
-0.584978 -0.569689 1.154667 Cluster 1 Q9Y4L1 
-0.582368 -0.572318 1.154686 Cluster 1 P07203 
-0.590786 -0.56381 1.154595 Cluster 1 Q01082 
-0.589435 -0.565181 1.154616 Cluster 1 P49327 
-0.589108 -0.565512 1.15462 Cluster 1 O75116 
-0.595769 -0.558733 1.154503 Cluster 1 O14818 
-0.596541 -0.557945 1.154485 Cluster 1 Q15019 
-0.596444 -0.558044 1.154488 Cluster 1 P68104 
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-0.548221 -0.605997 1.154219 Cluster 1 P08238 
-0.536429 -0.617327 1.153756 Cluster 1 Q12913 
-0.542805 -0.61122 1.154025 Cluster 1 P35237 
-0.508807 -0.64328 1.152088 Cluster 1 Q8WUM4 
-0.529712 -0.623713 1.153424 Cluster 1 Q6P3W7 
-0.518587 -0.634183 1.15277 Cluster 1 Q86TP1 
-0.527902 -0.625425 1.153327 Cluster 1 Q96FW1 
-0.814223 -0.301959 1.116182 Cluster 1 P09972 
-0.806207 -0.312804 1.11901 Cluster 1 P08107 
-0.807104 -0.311596 1.1187 Cluster 1 P51665 
-0.831558 -0.278039 1.109597 Cluster 1 P48637 
-0.824016 -0.288527 1.112542 Cluster 1 Q9UJ90 
-0.821211 -0.292395 1.113606 Cluster 1 P23229-2 
-0.826426 -0.285189 1.111615 Cluster 1 Q16851 
-0.851597 -0.249544 1.101141 Cluster 1 O00231 
-0.849761 -0.252194 1.101955 Cluster 1 P28676 
-0.847474 -0.255484 1.102958 Cluster 1 Q16555 
-0.844831 -0.25927 1.104101 Cluster 1 Q7KZF4 
-0.842004 -0.263303 1.105306 Cluster 1 P01111 
-0.844428 -0.259846 1.104274 Cluster 1 P53992 
-0.74091 -0.396546 1.137455 Cluster 1 P60842 
-0.728761 -0.4113 1.140061 Cluster 1 P40925 
-0.744885 -0.391664 1.13655 Cluster 1 P29144 
-0.746229 -0.390009 1.136238 Cluster 1 P25789 
-0.7379 -0.400223 1.138123 Cluster 1 P28066 
-0.746107 -0.390159 1.136266 Cluster 1 P00558 
-0.729542 -0.410359 1.139901 Cluster 1 P60981 
-0.770999 -0.358927 1.129926 Cluster 1 Q6IBS0 
-0.774759 -0.354114 1.128872 Cluster 1 P30085 
-0.778987 -0.34867 1.127656 Cluster 1 Q9NQP4 
-0.779284 -0.348286 1.12757 Cluster 1 O00299 
-0.785719 -0.339932 1.125651 Cluster 1 P36959 
-0.760289 -0.372498 1.132787 Cluster 1 Q96CW1 
-0.757937 -0.375451 1.133388 Cluster 1 Q99497 
-0.758671 -0.374531 1.133201 Cluster 1 P22694 
-1.001549 0.0031047 0.998444 Cluster 1 O75874 
-1.000401 0.000802 0.9995987 Cluster 1 P04040 
-1.00324 0.0065111 0.9967285 Cluster 1 P61421 
-1.007533 0.0152409 0.9922925 Cluster 1 P41226 
-1.009123 0.018502 0.9906207 Cluster 1 P51809 
-1.011155 0.0226966 0.9884585 Cluster 1 Q9NYU2 
-1.012339 0.0251529 0.9871863 Cluster 1 P55072 
-1.013246 0.0270398 0.9862059 Cluster 1 Q6NXT6-2 
-1.025588 0.0533076 0.97228 Cluster 1 Q7L1Q6 
-1.02108 0.0435851 0.9774948 Cluster 1 P20339 
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-1.021529 0.044547 0.9769821 Cluster 1 P43034 
-1.016672 0.0342228 0.9824493 Cluster 1 P16298 
-1.018586 0.0382706 0.9803153 Cluster 1 Q13576 
-1.017679 0.03635 0.9813294 Cluster 1 P06744 
-1.017508 0.0359872 0.9815206 Cluster 1 P08567 
-1.015335 0.0314108 0.9839245 Cluster 1 Q9HBI1 
-1.048161 0.1045347 0.9436264 Cluster 1 Q9BZH6 
-1.049532 0.1077976 0.9417341 Cluster 1 Q14697 
-1.048297 0.1048577 0.9434395 Cluster 1 Q9Y3C5 
-1.047361 0.1026399 0.9447216 Cluster 1 Q14974 
-1.047113 0.1020528 0.9450604 Cluster 1 Q13418 
-1.047903 0.1039214 0.9439812 Cluster 1 P63104 
-1.047699 0.1034383 0.9442605 Cluster 1 P07195 
-1.045538 0.0983435 0.9471948 Cluster 1 P60709 
-1.053388 0.1170837 0.9363042 Cluster 1 K7EQ37 
-1.051718 0.1130422 0.9386754 Cluster 1 Q14012 
-1.055811 0.1230016 0.9328095 Cluster 1 P37802 
-1.059072 0.1310709 0.9280013 Cluster 1 P23284 
-1.058034 0.1284889 0.9295452 Cluster 1 Q3ZCW2 
-1.063365 0.1418857 0.9214791 Cluster 1 Q8NG11 
-1.036786 0.0781597 0.9586267 Cluster 1 P55209 
-1.038699 0.0825103 0.9561886 Cluster 1 Q9Y490 
-1.03716 0.079007 0.9581529 Cluster 1 P14770 
-1.040707 0.0871144 0.9535929 Cluster 1 Q5JTZ9 
-1.042088 0.0903 0.9517875 Cluster 1 B8ZZI0 
-1.04007 0.0856499 0.9544203 Cluster 1 P05106 
-1.040418 0.0864482 0.9539695 Cluster 1 Q15056 
-1.029195 0.0612022 0.9679933 Cluster 1 Q96KP4 
-1.030424 0.0639136 0.9665102 Cluster 1 Q15833 
-1.030688 0.0644994 0.966189 Cluster 1 Q9UJU6 
-1.031441 0.0661683 0.9652727 Cluster 1 Q8N9U0 
-1.031518 0.0663404 0.965178 Cluster 1 P0C7P3 
-1.033548 0.0708649 0.9626825 Cluster 1 P11216 
-1.033808 0.0714476 0.9623601 Cluster 1 O00194 
-0.881129 -0.20574 1.086869 Cluster 1 P37837 
-0.883192 -0.202593 1.085785 Cluster 1 P48739 
-0.880157 -0.207219 1.087375 Cluster 1 P04406 
-0.883273 -0.202469 1.085742 Cluster 1 P51149 
-0.914375 -0.1535 1.067875 Cluster 1 P15153 
-0.913672 -0.15464 1.068312 Cluster 1 O95782 
-0.916697 -0.149723 1.066419 Cluster 1 P52565 
-0.928164 -0.1308 1.058964 Cluster 1 P36871 
-0.927245 -0.132332 1.059578 Cluster 1 P00491 
-0.928399 -0.130407 1.058806 Cluster 1 Q9H4M9 
-0.923091 -0.139227 1.062318 Cluster 1 P62937 
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-0.903359 -0.171183 1.074542 Cluster 1 P16885 
-0.90748 -0.164614 1.072093 Cluster 1 P62158 
-0.908548 -0.162901 1.071449 Cluster 1 P06733 
-0.909912 -0.16071 1.070622 Cluster 1 P49407 
-0.899046 -0.178002 1.077048 Cluster 1 E7ESP4 
-0.896878 -0.181408 1.078286 Cluster 1 Q15067-3 
-0.990667 -0.018411 1.009079 Cluster 1 O60331 
-0.988975 -0.021698 1.010672 Cluster 1 P61158 
-0.989769 -0.020158 1.009926 Cluster 1 P30566 
-0.992283 -0.015259 1.007542 Cluster 1 P63241 
-0.96398 -0.068517 1.032496 Cluster 1 O00154 
-0.965255 -0.0662 1.031455 Cluster 1 O75083 
-0.96453 -0.067519 1.032048 Cluster 1 Q15762 
-0.967165 -0.062719 1.029883 Cluster 1 Q9NQ75 
-0.982178 -0.034738 1.016916 Cluster 1 P16671 
-0.979314 -0.040161 1.019476 Cluster 1 Q13617 
-0.971477 -0.054793 1.02627 Cluster 1 P18206 
-0.972385 -0.053113 1.025498 Cluster 1 P06737 
-0.974223 -0.049701 1.023924 Cluster 1 P07384 
-0.975149 -0.047976 1.023124 Cluster 1 P07919 
-0.977057 -0.044407 1.021464 Cluster 1 Q86UX7 
-0.977074 -0.044375 1.021449 Cluster 1 P07741 
-0.95801 -0.079263 1.037273 Cluster 1 P60174 
-0.958389 -0.078585 1.036974 Cluster 1 Q14644 
-0.956464 -0.08202 1.038484 Cluster 1 P68371 
-0.956286 -0.082337 1.038623 Cluster 1 P08648 
-0.954309 -0.085846 1.040156 Cluster 1 Q96FN4 
-0.952145 -0.08967 1.041815 Cluster 1 P11142 
-0.952905 -0.08833 1.041235 Cluster 1 Q9Y6D6 
-0.950068 -0.093321 1.043389 Cluster 1 P07737 
-0.951283 -0.091188 1.042471 Cluster 1 P00488 
-0.948026 -0.096895 1.04492 Cluster 1 Q5HYI8 
-0.942282 -0.106854 1.049136 Cluster 1 P08514 
-0.943267 -0.105155 1.048422 Cluster 1 P25788 
-0.935258 -0.11886 1.054118 Cluster 1 Q9UPU5 
-0.938554 -0.113249 1.051803 Cluster 1 P29401 
-0.939015 -0.112461 1.051476 Cluster 1 Q14203 
-1.142234 0.4245728 0.7176617 Cluster 1 K7EM38 
-1.142742 0.4278251 0.714917 Cluster 1 O75608 
-1.142721 0.4276866 0.7150341 Cluster 1 P20020 
-1.14304 0.4297654 0.7132748 Cluster 1 P14625 
-1.142888 0.4287753 0.7141132 Cluster 1 O43150 
-1.147079 0.4588379 0.6882415 Cluster 1 P04792 
-1.14525 0.4449494 0.700301 Cluster 1 P19086 
-1.140232 0.4123089 0.7279232 Cluster 1 P15498 
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-1.139638 0.4088237 0.730814 Cluster 1 P21333-2 
-1.139037 0.4053638 0.7336729 Cluster 1 Q70IA8 
-1.138003 0.3995579 0.7384455 Cluster 1 Q15084 
-1.138201 0.4006563 0.737545 Cluster 1 Q8NFV4 
-1.137765 0.3982412 0.7395236 Cluster 1 O60610 
-1.148995 0.4752122 0.673783 Cluster 1 O95167 
-1.149084 0.4760334 0.6730509 Cluster 1 E9PSI1 
-1.149876 0.4836248 0.6662517 Cluster 1 O95486 
-1.151334 0.4993666 0.6519679 Cluster 1 O95373 
-1.151517 0.5015538 0.6499632 Cluster 1 Q15386 
-1.152507 0.5146445 0.6378625 Cluster 1 Q9H4B7 
-1.133605 0.3765259 0.7570789 Cluster 1 Q8NGA1 
-1.128595 0.3528632 0.775732 Cluster 1 P07900 
-1.126018 0.341509 0.7845092 Cluster 1 P00918 
-1.130783 0.3629115 0.7678711 Cluster 1 Q13200 
-1.129713 0.3579491 0.7717643 Cluster 1 P50995 
-1.129984 0.359198 0.7707865 Cluster 1 Q9NY33 
-1.110169 0.2800498 0.8301189 Cluster 1 P00390 
-1.114906 0.2971852 0.8177203 Cluster 1 Q12974 
-1.121918 0.3243682 0.7975497 Cluster 1 Q9H3U1 
-1.118141 0.3094293 0.8087116 Cluster 1 Q01813 
-1.119591 0.3150755 0.8045151 Cluster 1 P17858 
-1.08725 0.2068525 0.8803974 Cluster 1 Q15746 
-1.087493 0.2075626 0.8799302 Cluster 1 P30086 
-1.079927 0.1859591 0.8939674 Cluster 1 P62191 
-1.079814 0.1856458 0.8941683 Cluster 1 P31946 
-1.082716 0.1938022 0.8889135 Cluster 1 P04075 
-1.07229 0.1651395 0.9071507 Cluster 1 Q9NZN3 
-1.071304 0.1625167 0.9087878 Cluster 1 O75954 
-1.069341 0.1573335 0.9120071 Cluster 1 P06132 
-1.075955 0.1750156 0.900939 Cluster 1 P00338 
-1.095029 0.2302077 0.8648213 Cluster 1 O00442 
-1.094679 0.2291289 0.8655503 Cluster 1 Q05397 
-1.093105 0.2243092 0.868796 Cluster 1 P52209 
-1.104733 0.2613802 0.8433532 Cluster 1 P04899 
-1.105512 0.2639973 0.8415151 Cluster 1 O14980 
-1.10571 0.2646627 0.8410469 Cluster 1 Q9UEY8 
-1.100991 0.2490589 0.8519322 Cluster 1 P17252 
-1.100278 0.2467554 0.8535224 Cluster 1 Q13976-2 
-1.102479 0.2539103 0.8485689 Cluster 1 P31150 
-1.099276 0.2435419 0.8557338 Cluster 1 P35998 
-1.097353 0.2374485 0.8599042 Cluster 1 P50851 
-0.505342 1.151822 -0.64648 Cluster 2 O94905 
-0.556118 1.154443 -0.598325 Cluster 2 Q9UBQ0 
-0.524711 1.153147 -0.628436 Cluster 2 O00159 
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-0.608515 1.154129 -0.545614 Cluster 2 B4DQH6 
-0.609694 1.154085 -0.544391 Cluster 2 Q9BSJ8 
-0.437108 1.144136 -0.707028 Cluster 2 P30626 
-0.354253 1.128903 -0.77465 Cluster 2 Q10588 
-0.290774 1.113162 -0.822387 Cluster 2 P17987 
-1.034515 0.9614803 0.0730349 Cluster 3 Q13409 
-1.031075 0.9657186 0.0653567 Cluster 3 Q8N0Y7 
-1.030855 0.9659868 0.0648679 Cluster 3 Q14642 
-1.049584 0.9416614 0.1079226 Cluster 3 Q8NF37 
-1.043562 0.9498391 0.093723 Cluster 3 O75131 
-1.099825 0.8545256 0.245299 Cluster 3 O43776 
-1.09331 0.8683758 0.2249347 Cluster 3 O14579 
-1.114082 0.8199413 0.2941402 Cluster 3 Q9NVM1 
-1.106387 0.8394292 0.2669578 Cluster 3 Q01518-2 
-1.104222 0.8445497 0.2596723 Cluster 3 Q06187 
-1.114005 0.8201457 0.2938595 Cluster 3 P18031 
-1.079038 0.89555 0.1834878 Cluster 3 Q9Y315 
-1.077866 0.8976161 0.18025 Cluster 3 P68366 
-1.153925 0.5403289 0.6135966 Cluster 3 P52333 
-1.15456 0.5616607 0.592899 Cluster 3 Q9Y3A6 
-1.154465 0.5570385 0.5974266 Cluster 3 P51148 
-1.154673 0.5704717 0.5842016 Cluster 3 Q14432 
-1.15385 0.6152891 0.5385614 Cluster 3 P62140 
-1.153845 0.6154187 0.5384259 Cluster 3 P40616 
-1.127678 0.7789136 0.3487642 Cluster 3 Q15049 
-1.14308 0.7130542 0.4300256 Cluster 3 P50148 
-1.142228 0.7176976 0.4245302 Cluster 3 Q9UHD2 
-1.140687 0.7256673 0.4150193 Cluster 3 Q04759 
-1.140471 0.7267432 0.4137276 Cluster 3 P43405 
-1.141303 0.7225421 0.4187608 Cluster 3 P55160 
-1.13711 0.7424371 0.3946733 Cluster 3 O15498 
-1.135913 0.7476115 0.3883018 Cluster 3 O75915 
-1.14613 0.6946788 0.4514509 Cluster 3 Q96P48 
-1.148016 0.6814538 0.4665621 Cluster 3 Q9BT78 
-1.149842 0.6665552 0.4832872 Cluster 3 Q9UJ68 
-1.151876 0.6458439 0.5060318 Cluster 3 Q16539 
-0.848363 1.10257 -0.254207 Cluster 3 O60234 
-0.852816 1.100595 -0.24778 Cluster 3 Q63HN8 
-0.785416 1.125744 -0.340327 Cluster 3 P20073 
-0.949356 1.043925 -0.094569 Cluster 3 Q05209 
-0.937869 1.052288 -0.114419 Cluster 3 Q9UPT5 
-0.951807 1.042073 -0.090266 Cluster 3 Q9Y6W5 
-0.971142 1.026554 -0.055412 Cluster 3 O15269 
-1.000908 0.9990896 0.0018184 Cluster 3 Q01433 
-0.921241 1.063519 -0.142277 Cluster 3 O60888 
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-0.919592 1.06458 -0.144988 Cluster 3 Q96RD7 
-0.892435 1.080781 -0.188346 Cluster 3 P51153 
0.5516566 -1.154325 0.6026683 Cluster 4 B1AK87 
0.4878765 -1.150295 0.6624184 Cluster 4 Q9H0U4 
0.5102391 -1.152194 0.6419545 Cluster 4 O75746 
0.4432888 -1.145019 0.7017305 Cluster 4 Q96BY6 
0.4245389 -1.142229 0.7176903 Cluster 4 Q969M1 
0.8198218 -1.114126 0.2943043 Cluster 4 Q93050 
0.8015267 -1.120601 0.3190742 Cluster 4 Q15843 
0.7720492 -1.129634 0.3575848 Cluster 4 P60228 
0.7420198 -1.137205 0.3951852 Cluster 4 Q9BQE3 
0.7141064 -1.14289 0.4287833 Cluster 4 P20936 
0.7123886 -1.143199 0.4308107 Cluster 4 Q92499 
0.6857943 -1.147425 0.4616304 Cluster 4 Q9Y6A9 
0.6920593 -1.146523 0.4544642 Cluster 4 I3L440 
0.9650126 -1.031654 0.0666412 Cluster 4 Q8TF64 
0.9625983 -1.033616 0.0710173 Cluster 4 Q00796 
0.9825351 -1.016595 0.0340597 Cluster 4 P63096 
1.022744 -0.975587 -0.047157 Cluster 4 Q6PL24 
1.016817 -0.982289 -0.034528 Cluster 4 Q9Y2G8 
0.9236832 -1.061931 0.1382475 Cluster 4 P43250 
0.921083 -1.063621 0.1425378 Cluster 4 Q9P253 
0.8942859 -1.079748 0.1854624 Cluster 4 Q16181 
0.87511 0.2148536 -1.089964 Cluster 5 P51790 
0.8762422 0.2131466 -1.089389 Cluster 5 Q86UT6 
0.8698852 0.2226855 -1.092571 Cluster 5 O95563 
0.8588995 0.2389204 -1.09782 Cluster 5 P49411 
0.8571283 0.2415092 -1.098637 Cluster 5 Q8WVC6 
0.8951395 0.1841294 -1.079269 Cluster 5 Q2TAA5 
0.8866401 0.1973061 -1.083946 Cluster 5 P30038 
0.887756 0.1955881 -1.083344 Cluster 5 A6NFX1 
0.8957757 0.1831346 -1.07891 Cluster 5 P18054 
0.8867411 0.1971508 -1.083892 Cluster 5 O94919 
0.8105881 0.306893 -1.117481 Cluster 5 P22695 
0.813715 0.3026501 -1.116365 Cluster 5 P50416 
0.813476 0.302975 -1.116451 Cluster 5 O00400 
0.8164232 0.2989588 -1.115382 Cluster 5 Q6PIU2 
0.8187131 0.2958254 -1.114539 Cluster 5 Q15125 
0.8298819 0.2803806 -1.110263 Cluster 5 P13987 
0.8270578 0.2843117 -1.111369 Cluster 5 Q9P035 
0.8352891 0.2728039 -1.108093 Cluster 5 Q86YW5 
0.8414148 0.26414 -1.105555 Cluster 5 Q86VU5 
0.986454 0.0265627 -1.013017 Cluster 5 O95298 
0.9895095 0.0206608 -1.01017 Cluster 5 P35579 
0.9905518 0.018636 -1.009188 Cluster 5 P20674 
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0.9811796 0.0366341 -1.017814 Cluster 5 Q8WZA9 
0.9753326 0.0476325 -1.022965 Cluster 5 Q9BTZ2 
0.975701 0.0469446 -1.022645 Cluster 5 Q9H061 
0.9431745 0.1053152 -1.04849 Cluster 5 Q3KQZ1 
0.9462281 0.1000257 -1.046254 Cluster 5 P08962 
0.9643464 0.0678513 -1.032198 Cluster 5 Q9BS26 
0.9598472 0.0759721 -1.035819 Cluster 5 Q13586 
0.9541303 0.0861635 -1.040294 Cluster 5 P24557 
0.9553556 0.083991 -1.039347 Cluster 5 Q9UJZ1 
0.9558852 0.0830499 -1.038935 Cluster 5 P05121 
0.9561858 0.0825154 -1.038701 Cluster 5 P51659 
0.9559832 0.0828757 -1.038859 Cluster 5 Q14766 
0.9519175 0.090071 -1.041989 Cluster 5 Q9H7M9 
0.9491734 0.0948888 -1.044062 Cluster 5 O00151 
0.9229825 0.1394061 -1.062389 Cluster 5 Q96A26 
0.9200824 0.1441825 -1.064265 Cluster 5 P39656 
0.9155231 0.1516341 -1.067157 Cluster 5 Q9H3N1 
0.9179335 0.1477032 -1.065637 Cluster 5 Q92604 
0.905049 0.1684947 -1.073544 Cluster 5 Q9C0E8 
0.9014618 0.1741891 -1.075651 Cluster 5 Q9Y2Z4 
0.9103149 0.160062 -1.070377 Cluster 5 P10515 
0.9293803 0.1287652 -1.058145 Cluster 5 O75947 
0.9249159 0.1362055 -1.061121 Cluster 5 Q9Y251 
0.9327058 0.1231766 -1.055882 Cluster 5 P02671 
0.9337073 0.1214855 -1.055193 Cluster 5 O14653 
0.9359607 0.1176674 -1.053628 Cluster 5 Q9UBN7 
0.936091 0.1174459 -1.053537 Cluster 5 Q8NE86 
0.9388261 0.1127847 -1.051611 Cluster 5 P39210 
1.124087 -0.333304 -0.790783 Cluster 5 Q9NRZ7 
1.12849 -0.352391 -0.7761 Cluster 5 Q8TC12 
1.125137 -0.337734 -0.787403 Cluster 5 P48449 
1.113764 -0.292974 -0.82079 Cluster 5 Q9Y6C2 
1.117537 -0.307106 -0.810431 Cluster 5 Q12846 
1.116208 -0.302058 -0.81415 Cluster 5 P02776 
1.117097 -0.305427 -0.81167 Cluster 5 P35914 
1.110248 -0.28033 -0.829918 Cluster 5 P23368 
1.110963 -0.282864 -0.8281 Cluster 5 Q9BT22 
1.108521 -0.274287 -0.834235 Cluster 5 J3KN67 
1.105187 -0.262903 -0.842285 Cluster 5 Q9HDC9 
1.106748 -0.268187 -0.838561 Cluster 5 Q8WWA1 
1.107189 -0.269694 -0.837495 Cluster 5 Q8IYS2 
1.106421 -0.267074 -0.839347 Cluster 5 Q9NZC3 
1.105899 -0.265302 -0.840596 Cluster 5 P13073 
1.070383 -0.160079 -0.910305 Cluster 5 P02751 
1.068995 -0.156426 -0.912568 Cluster 5 Q9Y274 
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1.065502 -0.147355 -0.918146 Cluster 5 O43674 
1.066779 -0.150653 -0.916126 Cluster 5 Q16836 
1.063431 -0.142054 -0.921377 Cluster 5 O00217 
1.090229 -0.215645 -0.874584 Cluster 5 Q9BWM7 
1.094706 -0.229211 -0.865495 Cluster 5 Q9Y2G3 
1.080943 -0.188802 -0.892141 Cluster 5 P36551 
1.079931 -0.185971 -0.89396 Cluster 5 Q96HV5 
1.077022 -0.177932 -0.89909 Cluster 5 P27824 
1.086054 -0.203373 -0.882681 Cluster 5 P51575 
1.083769 -0.1968 -0.886969 Cluster 5 Q9P0L0 
1.084279 -0.198258 -0.886021 Cluster 5 Q9Y6N5 
1.028972 -0.06071 -0.968262 Cluster 5 Q13011 
1.024646 -0.051263 -0.973383 Cluster 5 Q6YHK3 
1.020252 -0.041815 -0.978436 Cluster 5 Q13642-1 
1.014428 -0.02951 -0.984918 Cluster 5 P20933 
1.009983 -0.020274 -0.989709 Cluster 5 O14561 
1.014418 -0.029488 -0.98493 Cluster 5 Q04941 
1.01113 -0.022644 -0.988486 Cluster 5 Q9BQA9 
1.017682 -0.036355 -0.981327 Cluster 5 O95674 
1.003062 -0.006152 -0.99691 Cluster 5 O14735 
0.9979499 0.0040876 -1.002038 Cluster 5 Q13505 
1.006279 -0.012678 -0.993601 Cluster 5 P36542 
1.002746 -0.005515 -0.997231 Cluster 5 Q14BN4 
1.037907 -0.080705 -0.957202 Cluster 5 O14523 
1.039786 -0.084997 -0.954789 Cluster 5 Q13201 
1.038826 -0.0828 -0.956026 Cluster 5 P35749 
1.035895 -0.076143 -0.959752 Cluster 5 O95427 
1.051194 -0.111782 -0.939412 Cluster 5 Q9H3P7 
1.0497 -0.1082 -0.9415 Cluster 5 Q9H7J1 
1.055023 -0.12107 -0.933953 Cluster 5 P24539 
1.041789 -0.089609 -0.95218 Cluster 5 Q6NVY1 
1.044118 -0.095018 -0.9491 Cluster 5 Q02218 
1.046432 -0.100446 -0.945986 Cluster 5 Q13423 
1.045934 -0.099272 -0.946661 Cluster 5 O15533 
1.046236 -0.099983 -0.946253 Cluster 5 Q8IZ81 
1.047288 -0.102467 -0.944821 Cluster 5 Q9UHQ9 
1.142977 -0.42935 -0.713627 Cluster 5 Q96MH6 
1.143569 -0.433269 -0.710301 Cluster 5 Q9HCE1 
1.145433 -0.446276 -0.699157 Cluster 5 P61009 
1.136308 -0.390383 -0.745926 Cluster 5 P02768 
1.132528 -0.371237 -0.761291 Cluster 5 P05166 
1.140925 -0.416455 -0.72447 Cluster 5 Q9UHQ4 
1.14061 -0.414556 -0.726053 Cluster 5 O43865 
1.13842 -0.401879 -0.736541 Cluster 5 P04843 
1.149488 -0.479834 -0.669654 Cluster 5 P04179 
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1.15424 -0.548897 -0.605344 Cluster 5 P30405 
1.153472 -0.530616 -0.622856 Cluster 5 P02675 
1.153392 -0.529103 -0.624289 Cluster 5 Q96NB2 
1.149222 -0.671903 -0.47732 Cluster 5 O60762 
1.14783 -0.68284 -0.46499 Cluster 5 P09486 
1.147228 -0.687194 -0.460034 Cluster 5 O95182 
1.1513 -0.652335 -0.498965 Cluster 5 P11182 
1.152536 -0.637474 -0.515062 Cluster 5 Q9BSF4 
1.154607 -0.590039 -0.564568 Cluster 5 Q9NS69 
1.154643 -0.58727 -0.567373 Cluster 5 Q96HD1 
1.153831 -0.615716 -0.538115 Cluster 5 P07477 
1.153363 -0.624809 -0.528554 Cluster 5 Q9Y3E5 
1.153414 -0.623907 -0.529507 Cluster 5 P32189 
1.154256 -0.604858 -0.549398 Cluster 5 Q9NZ45 
1.100761 -0.852448 -0.248313 Cluster 5 Q9UBV2 
1.089383 -0.876253 -0.213131 Cluster 5 O95140 
1.090611 -0.873827 -0.216784 Cluster 5 Q5VY43 
1.125486 -0.786263 -0.339223 Cluster 5 P10909 
1.127935 -0.778029 -0.349906 Cluster 5 P00367 
1.128875 -0.774748 -0.354128 Cluster 5 D6RIE3 
1.121385 -0.799172 -0.322213 Cluster 5 Q8IWA5 
1.118165 -0.808644 -0.309521 Cluster 5 P19367 
-0.227321 1.094091 -0.86677 Cluster 6 P67812 
-0.16435 1.071994 -0.907644 Cluster 6 Q86WI1 
-0.193404 1.082575 -0.889171 Cluster 6 A1L0T0 
-0.087448 1.040852 -0.953404 Cluster 6 P02656 
-0.047344 1.022831 -0.975487 Cluster 6 Q9H845 
-0.018344 1.009046 -0.990702 Cluster 6 Q9NXH8 
0.0025953 0.9986998 -1.001295 Cluster 6 Q6ZRH9 
0.3096433 0.808553 -1.118196 Cluster 6 O00264 
0.3089626 0.8090572 -1.11802 Cluster 6 O75955 
0.2729767 0.8351663 -1.108143 Cluster 6 Q14165 
0.2798586 0.8302559 -1.110115 Cluster 6 Q5K4L6 
0.3346477 0.7897593 -1.124407 Cluster 6 O60831 
0.333151 0.7908992 -1.12405 Cluster 6 O43561 
0.3438243 0.7827284 -1.126553 Cluster 6 Q05682 
0.3439388 0.7826403 -1.126579 Cluster 6 Q6UXV4 
0.3590273 0.7709203 -1.129948 Cluster 6 Q14677 
0.3656352 0.7657251 -1.13136 Cluster 6 Q15526 
0.1709799 0.9034865 -1.074466 Cluster 6 P49748 
0.1959979 0.88749 -1.083488 Cluster 6 P02775 
0.2003417 0.8846628 -1.085005 Cluster 6 P06753 
0.1847758 0.8947257 -1.079502 Cluster 6 Q8TDM6 
0.2553587 0.8475611 -1.10292 Cluster 6 Q93084-2 
0.2395118 0.8584954 -1.098007 Cluster 6 O95573 
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0.2150426 0.8749844 -1.090027 Cluster 6 P01891 
0.2215878 0.8706204 -1.092208 Cluster 6 O96008 
0.221614 0.8706029 -1.092217 Cluster 6 Q15363 
0.1173058 0.9361735 -1.053479 Cluster 6 P12236 
0.1182741 0.9356033 -1.053877 Cluster 6 P12074 
0.7821378 0.3445909 -1.126729 Cluster 6 P62341 
0.7854814 0.3402424 -1.125724 Cluster 6 P30049 
0.7731604 0.3561629 -1.129323 Cluster 6 P61073 
0.7391602 0.3986853 -1.137845 Cluster 6 P27338 
0.7347651 0.4040384 -1.138803 Cluster 6 P61619 
0.7469215 0.389154 -1.136075 Cluster 6 P43304 
0.7527217 0.3819646 -1.134686 Cluster 6 Q96G23 
0.7575126 0.3759828 -1.133495 Cluster 6 Q9Y487 
0.7614167 0.3710786 -1.132495 Cluster 6 Q969X5 
0.7579426 0.3754439 -1.133386 Cluster 6 P09622 
0.7203373 0.4213911 -1.141728 Cluster 6 P48047 
0.7075265 0.4365245 -1.144051 Cluster 6 Q5VWC8 
0.7127409 0.4303953 -1.143136 Cluster 6 P04844 
0.707095 0.4370298 -1.144125 Cluster 6 P07996 
0.6406387 0.5116581 -1.152297 Cluster 6 P15121 
0.6501635 0.5013355 -1.151499 Cluster 6 P38117 
0.6479989 0.503692 -1.151691 Cluster 6 Q7Z7H5 
0.6726753 0.4764545 -1.14913 Cluster 6 Q96ER9 
0.6720912 0.4771087 -1.1492 Cluster 6 O43306 
0.6685157 0.4811041 -1.14962 Cluster 6 H7BYY1 
0.6771619 0.4714121 -1.148574 Cluster 6 P35232 
0.6859699 0.4614304 -1.1474 Cluster 6 Q9UFN0 
0.6933592 0.4529702 -1.146329 Cluster 6 P08913 
0.4198109 0.7216627 -1.141474 Cluster 6 P16615 
0.4190405 0.7223079 -1.141348 Cluster 6 Q9UBF2 
0.4120217 0.7281619 -1.140184 Cluster 6 Q96LW7-2 
0.4124805 0.7277805 -1.140261 Cluster 6 O43169 
0.45107 0.6950094 -1.146079 Cluster 6 Q9H444 
0.4302529 0.7128617 -1.143114 Cluster 6 P02679 
0.4380286 0.7062414 -1.14427 Cluster 6 Q9UIQ6 
0.5150383 0.6374958 -1.152534 Cluster 6 P46977 
0.5342592 0.6193947 -1.153654 Cluster 6 O60704 
0.532912 0.6206762 -1.153588 Cluster 6 P48509 
0.4831066 0.6667176 -1.149824 Cluster 6 Q96QS1 
0.4809377 0.6686649 -1.149603 Cluster 6 P09669 
0.5613524 0.5932016 -1.154554 Cluster 6 P40197 
0.5582105 0.5962809 -1.154491 Cluster 6 Q9Y3B3 
0.5723994 0.582287 -1.154686 Cluster 6 Q14643 
0.5802211 0.5744746 -1.154696 Cluster 6 P21926 
0.5882288 0.566403 -1.154632 Cluster 6 P43307 
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0.6012624 0.5531033 -1.154366 Cluster 6 Q9Y276 
0.6197206 0.5339168 -1.153637 Cluster 6 Q7L1W4 
 
Table 2. Dataset of significantly changed soluble proteins after cluster analysis 
ADP Collagen 
Thr. & 
Collagen Cluster Accession 
-1.053985 0.1185352 0.9354495 Cluster 1 P49327 
-1.03846 0.0819644 0.9564953 Cluster 1 P06744 
-1.002334 0.0046855 0.997649 Cluster 1 Q92499 
-0.9447944 -0.1025138 1.047308 Cluster 1 O95295 
-1.154282 0.5502121 0.6040697 Cluster 1 P51148 
-1.15199 0.5075223 0.6444681 Cluster 1 P61224 
-1.152938 0.5212321 0.6317056 Cluster 1 Q9UIA9 
-1.146223 0.4521604 0.6940628 Cluster 1 Q684P5 
-1.110773 0.2821889 0.8285844 Cluster 1 P55060 
-1.109835 0.2788745 0.8309605 Cluster 1 Q86VP6 
-1.104945 0.2620884 0.8428563 Cluster 1 Q9BT78 
-1.099652 0.2447466 0.8549058 Cluster 1 Q08752 
-1.097471 0.2378197 0.859651 Cluster 1 P22234 
-1.08603 0.2033035 0.8827266 Cluster 1 P12429 
-1.130738 0.3627031 0.768035 Cluster 1 Q32MZ4 
-1.117356 0.3064151 0.810941 Cluster 1 Q7L576 
-1.121113 0.3211222 0.799991 Cluster 1 Q8NBF2 
-1.126833 0.781787 0.3450459 Cluster 1 O95373 
-1.128526 0.775975 0.3525509 Cluster 1 P41250 
-1.13287 0.7599642 0.3729062 Cluster 1 Q9C0C9 
-1.131035 0.7669388 0.3640958 Cluster 1 P17252 
-1.130082 0.7704344 0.3596473 Cluster 1 P20339 
-1.116252 0.814029 0.3022228 Cluster 1 Q9UJ70 
-1.15126 0.6527637 0.4984967 Cluster 1 O14617 
-1.150159 0.663685 0.4864739 Cluster 1 Q13045 
-1.149781 0.6671054 0.4826751 Cluster 1 Q15056 
-1.145733 0.6972504 0.4484829 Cluster 1 P52333 
-0.8686172 1.093193 -0.2245755 Cluster 2 O00410 
-0.8355334 1.107993 -0.27246 Cluster 2 P68371 
-0.9027758 1.074884 -0.1721078 Cluster 2 Q08AM6 
-0.8992599 1.076925 -0.1776648 Cluster 2 O00264 
-0.9268119 1.059866 -0.1330543 Cluster 2 Q13057 
-0.777661 1.128041 -0.3503803 Cluster 2 Q9BSF0 
-1.056427 0.9319108 0.1245163 Cluster 2 P16278 
-0.9940099 1.005884 -0.0118744 Cluster 2 P35749-3 
-0.0970316 1.044979 -0.9479473 Cluster 2 Q9Y265 
-0.0863097 1.040357 -0.9540477 Cluster 2 P30048 
-0.0354946 1.017275 -0.9817801 Cluster 2 P36543 
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-0.0398619 1.019335 -0.979473 Cluster 2 P18085 
0.0817288 0.9566276 -1.038356 Cluster 2 P14543 
-0.2705474 1.107438 -0.8368905 Cluster 2 Q15118 
-0.3012677 1.115998 -0.8147305 Cluster 2 P07437 
-0.2273059 1.094086 -0.8667802 Cluster 2 Q99798 
-0.427606 1.142708 -0.7151022 Cluster 2 P61604 
-0.4152507 1.140725 -0.7254744 Cluster 2 Q14258 
-0.5723566 1.154686 -0.5823295 Cluster 2 Q13201 
-0.5477464 1.154203 -0.6064565 Cluster 2 O00186 
-0.5321098 1.153548 -0.6214384 Cluster 2 Q9NY65 
-0.2229005 -0.8697411 1.092642 Cluster 3 Q9H2M9 
-0.1878234 -0.8927705 1.080594 Cluster 3 P00488 
-0.2039687 -0.8822908 1.086259 Cluster 3 P47755 
-0.281084 -0.8293775 1.110461 Cluster 3 P62191 
-0.4108858 -0.7291049 1.139991 Cluster 3 Q7Z460 
0.1667686 -1.0729 0.9061314 Cluster 3 P18433 
0.2418448 -1.098743 0.8568983 Cluster 3 Q9Y490 
0.2603735 -1.104432 0.8440587 Cluster 3 P32321 
0.0537566 -1.025794 0.9720375 Cluster 3 Q16363 
-0.0503577 -0.9738697 1.024227 Cluster 3 P30740 
-0.5311452 -0.622354 1.153499 Cluster 3 Q5VVQ6 
-0.6426218 -0.5095188 1.152141 Cluster 3 O15327 
-0.6047277 -0.549533 1.154261 Cluster 3 Q01518-2 
-0.6226315 -0.5308526 1.153484 Cluster 3 Q8N5N7 
-0.8331758 -0.2757729 1.108949 Cluster 3 Q13813 
-0.8043911 -0.3152417 1.119633 Cluster 3 P49257 
0.6977954 -1.145648 0.4478527 Cluster 4 O15117-2 
0.4797578 -1.14948 0.6697223 Cluster 4 Q9UL46 
0.53811 -1.153831 0.6157209 Cluster 4 Q9UBV8 
0.5832486 -1.15468 0.5714318 Cluster 4 P68133 
0.3746625 0.7585657 -1.133228 Cluster 5 Q16706 
0.3779742 0.7559212 -1.133895 Cluster 5 P40939 
0.2641683 0.8413948 -1.105563 Cluster 5 P02763 
0.4736593 0.6751655 -1.148825 Cluster 5 P00387 
0.5220804 0.6309093 -1.15299 Cluster 5 P46063 
0.7716715 0.3580676 -1.129739 Cluster 5 Q9UHQ9 
0.7282298 0.4119399 -1.14017 Cluster 5 P30084 
0.7479907 0.387833 -1.135824 Cluster 5 P02679 
0.6968491 0.4489467 -1.145796 Cluster 5 P05121 
0.6697477 0.4797294 -1.149477 Cluster 5 P09486 
0.6582366 0.492492 -1.150729 Cluster 5 P02675 
0.631094 0.5218838 -1.152978 Cluster 5 P02768 
1.077674 -0.1797212 -0.8979528 Cluster 6 P16284 
1.055766 -0.1228921 -0.9328744 Cluster 6 Q9UII2 
1.054848 -0.120642 -0.9342061 Cluster 6 P10720 
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1.065631 -0.1476876 -0.9179431 Cluster 6 P60891 
1.063429 -0.1420497 -0.9213795 Cluster 6 Q15365 
1.008932 -0.0181098 -0.9908221 Cluster 6 P04792 
0.9998169 0.0003661 -1.000183 Cluster 6 P18859 
1.018202 -0.0374572 -0.9807451 Cluster 6 Q9NTJ5 
1.019166 -0.0395025 -0.9796634 Cluster 6 Q14344 
1.026088 -0.054397 -0.9716913 Cluster 6 P10124 
0.9481615 0.0966577 -1.044819 Cluster 6 P04003 
0.9438235 0.104194 -1.048018 Cluster 6 P05067 
0.9539104 0.0865528 -1.040463 Cluster 6 P10909 
0.9756541 0.0470321 -1.022686 Cluster 6 P07996 
0.9740278 0.0500638 -1.024092 Cluster 6 P02671 
0.8619419 0.2344552 -1.096397 Cluster 6 P53990 
0.8776724 0.2109856 -1.088658 Cluster 6 Q96J92 
0.9104578 0.159832 -1.07029 Cluster 6 P48449 
0.9192192 0.1455987 -1.064818 Cluster 6 P02775 
1.153975 -0.6124327 -0.5415422 Cluster 6 P43034 
1.154148 -0.6080086 -0.5461394 Cluster 6 P67936-2 
1.154157 -0.6077498 -0.5464075 Cluster 6 Q9Y6C2 
1.153454 -0.6231738 -0.5302805 Cluster 6 P21912 
1.152896 -0.6323369 -0.5205588 Cluster 6 P04275 
1.154341 -0.5522023 -0.6021382 Cluster 6 Q96C24 
1.154514 -0.5592663 -0.5952474 Cluster 6 P51149 
1.154695 -0.5742682 -0.5804269 Cluster 6 P24752 
1.154587 -0.5913356 -0.5632511 Cluster 6 P68871 
1.151199 -0.6534145 -0.4977848 Cluster 6 P49753 
1.150242 -0.662917 -0.4873246 Cluster 6 Q96G03 
1.149211 -0.672003 -0.4772076 Cluster 6 Q06830 
1.14474 -0.4413062 -0.7034338 Cluster 6 P28676 
1.145113 -0.4439611 -0.7011521 Cluster 6 Q15208 
1.139054 -0.4054612 -0.7335925 Cluster 6 P48047 
1.141561 -0.4203529 -0.7212083 Cluster 6 Q6ZRH9 
1.142407 -0.425669 -0.7167377 Cluster 6 P22307 
1.142098 -0.4237065 -0.7183911 Cluster 6 P10606 
1.153676 -0.5347185 -0.6189573 Cluster 6 P02751 
1.152828 -0.5194938 -0.6333347 Cluster 6 Q9Y251 
1.149344 -0.478467 -0.6708775 Cluster 6 O75563 
1.150488 -0.489907 -0.6605813 Cluster 6 P04004 
1.127853 -0.3495432 -0.7783101 Cluster 6 Q5HYI8 
1.128514 -0.3524962 -0.7760175 Cluster 6 P30042 
1.125121 -0.3376674 -0.7874537 Cluster 6 P01137 
1.126171 -0.3421667 -0.7840038 Cluster 6 P14649 
1.131622 -0.3668786 -0.7647432 Cluster 6 M0R042 
1.114237 -0.2947133 -0.8195239 Cluster 6 P36776 
1.116423 -0.3028688 -0.8135541 Cluster 6 Q14766 
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1.115403 -0.299036 -0.8163666 Cluster 6 O95182 
1.115428 -0.2991325 -0.8162959 Cluster 6 P10809 
0.9156253 -1.067093 0.1514679 Cluster 6 P52209 
0.8953103 -1.079173 0.1838625 Cluster 6 P08133 
0.8828682 -1.085956 0.2030873 Cluster 6 Q9Y4L1 
0.961387 -1.03459 0.0732029 Cluster 6 Q13418 
0.9458901 -1.046503 0.1006132 Cluster 6 O00161 
0.9912961 -1.008482 0.0171864 Cluster 6 P61952 
1.025249 -0.9726772 -0.0525717 Cluster 6 Q9NYU2 
1.033387 -0.9628813 -0.0705056 Cluster 6 Q9Y6E0 
1.063331 -0.921532 -0.1417986 Cluster 6 P46379 
1.056438 -0.931895 -0.1245428 Cluster 6 P50440 
1.048262 -0.9434884 -0.1047732 Cluster 6 Q0ZGT2 
1.07481 -0.9029018 -0.171908 Cluster 6 Q9UDY2 
1.093024 -0.8689609 -0.2240637 Cluster 6 P37840 
1.093358 -0.8682792 -0.2250785 Cluster 6 Q9BS40 
1.104856 -0.843065 -0.261791 Cluster 6 P51970 
1.100996 -0.8519216 -0.2490741 Cluster 6 O75347 
1.101325 -0.8511834 -0.2501413 Cluster 6 P14618-2 
1.098941 -0.856467 -0.2424738 Cluster 6 P33908 
1.098796 -0.8567828 -0.2420132 Cluster 6 O60925 
1.138163 -0.7377206 -0.4004422 Cluster 6 Q8N841 
1.13717 -0.7421763 -0.3949933 Cluster 6 P09622 
1.136183 -0.7464616 -0.3897216 Cluster 6 Q04917 
1.118979 -0.8062969 -0.3126826 Cluster 6 Q15075 
1.116122 -0.8143879 -0.3017343 Cluster 6 Q8IZ83 
1.11227 -0.824727 -0.287543 Cluster 6 Q92614 
1.124618 -0.78908 -0.3355384 Cluster 6 Q15819 
1.126057 -0.7843807 -0.3416762 Cluster 6 Q5VZU9 
1.129947 -0.7709207 -0.3590267 Cluster 6 P69905 
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ABSTRACT 
As previously shown, platelet activation is mediated by different platelet membrane receptor and 
their activity in response to stimuli. These receptors are mainly phosphorylated and glycosylated. 
With the aim of investigating these receptors activity, in this study we also carried out a PTMs 
analysis of PMPs. Relevant platelet agonist such as ADP, thrombin and collagen were used for the 
activation. Thrombin, which is mostly used to generate PMPs in vitro was set as control. By using 
previously published protocols for the simultaneous enrichment of phosphorylated and glycosylated 
peptides, we identified 1225 unique phosphopeptides assigned to 614 phosphoproteins and 1245 
unique glycosylated peptides assigned to 533 unique glycoproteins. By performing an iTRAQ-
based quantitative experiment and following a known physiological agonist strength scale, our 
results revealed that glycosylation on focal adhesion related proteins as integrins is related to the 
agonist strength used for platelet activation.  
1. INTRODUCTION 
Platelet-derived microparticles (PMPs) are a heterogeneous population of vesicles (0.1-1 m) 
generated from the plasma membrane upon platelet activation by various stimuli or apoptosis. 
Microparticles are released from several cell types such as leukocytes, erythrocytes, endothelial and 
cancer cells [1]. Recently, it was shown that adipocytes [2], megakaryocytes [3] and central nervous 
system related cells [4] are known to release microparticles. However, those generated from 
activated platelet represent the major population of circulating microparticles in the human plasma 
[5]. Exosomes, which are known to be secreted from activated platelet as well, are smaller on 
average than PMPs (0.04 and 0.1 m) and stored within -granules. [6]. Elevated PMP levels have 
been detected in several pathological conditions such as uremia [7], infectious diseases [8,9], acute 
coronary syndrome [10], ischemic attack [11], immune thrombocytopenic purpura [12], diabetes 
mellitus [13] and cancer [14,15]. PMPs were shown to bind to hematopoietic progenitors improving 
their engraftment [16] and endothelial cells protecting them from apoptosis [17]. Multiple pathways 
are involved in platelet activation, including those induced by biomechanical such as high shear 
stress [18] and biochemical agonist such as ADP, collagen, epinephrine, serotonin and thrombin 
[19-22]. Activations promoted by those agonists are also defined sustained calcium induced platelet 
(SCIP) morphology, due to the role of intracellular Ca
2+
 concentration for the microparticles 
generation. In particular, breakage of the contact between platelet glycoprotein Ib beta chain and 
cytoskeleton is the trigger event in mechanical platelet stimulation [23] as well as integrin αIIbβ3 
receptor activity in biochemical activation [24]. However, microparticles shedding is known to be 
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driven by common steps such as signalling receptors recognition, cytoskeletal remodelling, 
calpain/caspase activity and mitochondrial depolarization [25]. Platelet membrane receptors play a 
central role during activation and primary hemostasis, interestingly most of these proteins are 
glycosylated and phosphorylated such as integrins [26]. However, platelet membrane glycoproteins 
were shown to mediate, by acting as receptors, several functions such as adhesion to the 
subendothelial matrix and platelet-platelet aggregation [27]. Platelet membrane glycoproteins were 
shown to be also involved in pathological conditions such as Bernard-Soulier syndrome [28], 
coronary artery [29] and renal diseases [30]. Platelet N-glycoproteome has been already elucidated 
[31,32] as well as platelet phosphoproteome has been intensely investigated [33-35]. However, 
phosporylated and glycosylated sites have, respectively, still to be elucidated in platelet derived 
microparticles. In this study, we performed a comprehensive proteomic analysis aimed to 
characterize the membrane phosphoproteome and glycoproteome of PMPs. In addition, by using 
iTRAQ-based quantitative proteomics we were able to quantify membrane-associated 
phosphoproteins and glycoproteins from differentially activated platelet samples. In particular, 
known physiological agonists were used for platelet activation; those agonists were chosen 
according to a previously reported agonist strength scale [36]. Thrombin, which is mostly used to 
generate PMPs in vitro was set as control [37]. Modified peptide enrichments were carried out using 
previously published method with minor modifications [38-41]. Our analysis revealed the 
membrane phosphoproteome and glycoproteome of PMPs showing also by using quantitative 
proteomics that glycosylation on focal adhesion associated proteins, mainly integrins, is related to 
the agonist strength used for platelet activation. 
2. MATERIALS AND METHODS 
All chemicals were purchased from Sigma (St. Louis, MO, USA) unless stated otherwise. Ultrapure 
water was from an ELGA Purelab Ultra water system (Bucks, U.K.). 
Microparticles isolation  - PMPs were obtained from fresh apheresis platelet provided by 
three healthy subject in accordance with the guidelines of the University of Southern Denmark 
(SDU) and the Odense University Hospital (OUH). Platelets were isolated and activated as 
previously described with minor modifications [42,43]. Briefly, platelets were pelleted by 
centrifugation at 700 x g for 20 min at 20°C. The pellet was washed twice with 137 mmol l
-1
 NaCl, 
2.6 mmol l
-1
 KCl, 1 mmol l
-1
 MgCl2, 11.9 mmol l
-1
 NaHCO3, 5.6 mmol l
-1
 D-Glucose and 1 mmol l
-
1
 EDTA (Buffer A, pH = 6.5), and resuspended in buffer A without EDTA (Buffer B, pH = 6). 
Platelet suspensions were divided in four aliquots of 5 ml each and stimulated in presence of a) 10 
mol l-1 ADP [42], b) 1 U ml-1 thrombin, c) 20 µg ml-1 collagen and d) 1 U ml-1 thrombin plus 20 
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g ml-1 collagen. The mixtures were incubated for 10 min at 37°C for ADP stimulation and for 30 
min at 37°C for the other treatments. Finally, the activations were stopped by adding 2.5 mmol l
-1
 
final concentration of EDTA or 2 mmol l
-1
 EGTA in the case of the ADP stimulation. Activated 
platelets were removed by centrifugation at 700 x g and 1,000 x g for 20 min at 20°C and the 
supernatants containing platelet derived MPs suspensions were collected. Platelet derived MPs were 
then pelleted by centrifugation at 130,000 x g for 60 min at 4°C.  
MP lysis and protein digestion – PMPs pellets were resuspended in ice-cold Na2CO3 buffer 
(0.1 M, pH = 11) containing protease inhibitor (Roche complete EDTA free, Meylan, France), 
PhosSTOP phosphatase inhibitor cocktail (Roche, Meylan, France) and 10 mM sodium pervanadate 
on ice. The suspension was tip probe sonicated for 20 sec (amplitude = 50%) twice and incubated 
on ice for 60 min to lyse the microparticles. The lysate was then centrifuged at 100,000 x g for 90 
min at 4°C to enrich membrane proteins (pellet). The supernatant (soluble proteins) was 
concentrated using 10 kDa cutoff Amicon ultra centrifugal filters units (Millipore, Billerica, 
MA,USA) whereas membrane fraction was redissolved directly in urea 6 M, thiourea 2 M and tip 
probe sonicated for 20 sec (amplitude = 20%). Both fractions were reduced in 10 mM dithiothreitol 
(DTT) for 30 min and then alkylated in 20 mM iodoacetamide (IAA) for 30 min at room 
temperature in the dark. Lysyl Endopeptidase C (Wako, Osaka, Japan) was added for 3 h (1:100 
w/w) and then the samples were diluted  8 times with 50 mM triethylammonia bicarbonate (TEAB, 
pH = 8). Trypsin was added at a ratio of 1:50 (w/w) and left overnight at 37°C to digest. Following 
incubation, samples were acidified with formic acid (2% final concentration) and centrifuged at 
14,000 x g for 10 min to stop trypsin digestion and precipitate insoluble material such as lipids. The 
supernatant was purified using in-house packed staged tips with Poros R2 and Oligo R3 reversed 
phase resins (Applied Biosystem, Foster City, CA, USA). Briefly, a small plug of C18 material (3M 
Empore) was inserted in the constricted end of a P200 tips, followed by packing of the stage tip 
with the resin (resuspended in 100% ACN) by applying gentle air pressure. The acidified sample 
was loaded onto the micro-column, after equilibration of the column with 0.1% trifluoroacetic acid 
(TFA), washed twice with 0.1% TFA and peptides were eluted with 60% ACN/0.1% TFA. A small 
amount of purified peptides (6 µl) was dried down and subjected to amino acid composition 
analysis to determine the concentration, while the remaining sample was lyophilized prior to 
iTRAQ labeling.  
iTRAQ labeling and peptide fractionation – Equal amount of peptides from each condition 
were iTRAQ 4-plex
TM
 labeled according to manufacturer’s instructions (Applied Biosystem, Foster 
City, CA, USA). Labeled peptides were combined in 1:1:1:1 proportion based on the quantification 
 74 
 
achieved from the amino acid composition analysis and MALDI-MS/MS analysis (Bruker 
Daltonics, Billerica, CA, USA, in lift mode). The samples were labeled as follow: ADP, iTRAQ-
114; thrombin (control), iTRAQ-115; collagen, iTRAQ-116; thrombin plus collagen, iTRAQ-117.  
Simultaneous enrichment of phosphopeptides and formerly N-sialylated glycopeptides - The 
peptide mixture was resuspended in TiO2 loading buffer (80% ACN, 5% TFA, 1 M glycolic acid). 
The optimal amount of TiO2 beads (0.6 mg/100 μg peptide mixture) was added and the tube was 
mixed on a shaker at room temperature for 10 minutes. After incubation, the sample was 
centrifuged to pellet the beads. The supernatant was removed carefully without disturbing the 
beads. The beads were washed first with 100 μL of washing buffer 1 (80% ACN, 1% TFA) and 
with washing buffer 2 (20% ACN, 0.1% TFA), mixed for 15 s, centrifuged to pellet the beads, and 
the solvent was collected. This final step was performed in order to remove peptides that bind to 
TiO2 due to hydrophilic interactions (mainly N-linked glycopeptides). The TiO2 beads were dried in 
the vacuum centrifuge. The TiO2 beads were subsequently incubated with 100 μL of pH = 11.3 
ammonia solution under shaking. After incubation, the beads were pelleted, the peptides were 
eluted  and dried by lyophilization prior to SIMAC. The peptides were redissolved in 50mM TEAB (pH 
= 8) and treated with PNGaseF (Roche) and Sialidase A (Prozyme, CA, USA) overnight at 37°C to remove 
linked glycans, the mixture was then acidified and dried. After deglycosylation, the SIMAC peptide 
enrichment was performed essentially as previously described [38]. Briefly, the lyophilized peptides 
were redissolved in 200 μL of 50% ACN, 0.1% TFA. The pH was adjusted to 1.6-1.8 using 10% 
TFA. A total of 70 μL of IMAC slurry (PhosSelect, Sigma-Aldrich, St. Louis, MO, USA) were 
washed twice with 50% ACN, 0.1% TFA prior to incubation with the peptide solution. The IMAC 
beads were incubated with the peptide solution for 30 min at room temperature under shaking. After 
incubation, the solution was introduced into a constricted 200 μL GeLoader tip and the liquid 
pressed through the tip using gentle air pressure. The flow through was collected (containing 
monophosphorylated and formerly N-sialylated peptides). The IMAC column was washed with 60 
μL of the loading buffer (50% ACN, 0.1% TFA), which was collected together with the flow 
through. The multiply phosphorylated peptides were subsequently eluted from the IMAC material 
using 80 μL of pH = 11.3 ammonia solution. The IMAC flow through was adjusted to 70% ACN, 
1% TFA and incubated for 10 min under continuous shaking with the same amount of TiO2 material 
as used in the first TiO2 purification. After incubation, the beads were pelleted by centrifugation, 
and the supernatant was collected and subsequently incubated with half the amount of TiO2 beads 
for 10 min under continuous shaking. After the second incubation, the beads were pelleted by 
centrifugation and the supernatant was collected (sialylated N-linked glycopeptides). The two pools 
of TiO2 beads were washed once with 50% ACN, 0.1% TFA and the beads were pelleted. After 
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drying the TiO2 beads in a vacuum centrifuge, the mono phosphorylated peptides were incubated 
with 100 μL of  pH = 11.3 ammonia solution for 10 min under continuous shaking. All of peptide 
samples were purified using Poros Oligo R3 RP microcolumns. 
Enrichment of N-linked glycopeptides - N-linked glycopeptides were enriched using an 
homemade HILIC micro-column. Briefly, a small plug of C8 material (3M Empore) was inserted in 
the constricted end of a P200 tips, followed by packing of the stage tip with 
PolyHYDROXYETHYL A
TM
  (PolyLC, Columbia, MD), resuspended in 100% ACN, by applying 
a gentle pressure. The peptide samples, containing the flow though  and the N-linked peptide 
fractions of the first TiO2 pre-purification, were resuspended in 80% ACN 1% TFA, loaded onto the 
micro-column, washed twice with 80% ACN 0.1% TFA and N-linked glycopeptides were eluted 
with 0.1% TFA. Samples were dried down, redissolved in 50mM TEAB (pH = 8) and treated with 
PNGaseF overnight at 37°C to remove N-linked glycans. After deglycosylation, N-linked 
deglycosylated peptides were purified using Poros Oligo R3 RP microcolumns. 
Peptide fractionation – Formerly N-sialylated deglycopeptide samples were fractionated by 
using hydrophilic interaction chromatography (HILIC) on an Agilent 1200 HPLC system. Samples 
were loaded onto a 450 µm OD x 320 µm ID x 17 cm micro-capillary column packed with TSK-gel 
Amide 80 (3 µm, Tosoh Bioscience, Japan). Peptides were resuspended in solvent B (90% ACN 
0.1% TFA) and eluted over a gradient of 100% to 60% solvent B (solvent A = 0.1% TFA) over 35 
min, followed by 60% to 0% over 7 min at a flow rate of 6 µl/min. HILIC fractions were combined 
into eight samples and lyophilized [44]. 
Reversed phase nLC-MS/MS - Dried fractions were resuspended in 0.1% FA (solvent A) and 
loaded onto a Ultimate 3000 RSLC nanoLC system (Thermo Fisher Scientific) coupled to a Q-
Exactive Plus mass spectrometer (Thermo Fisher Scientific, Bremen, Germany). The peptides were 
loaded onto a two-columns setup employing an Acclaim PepMap 100 precolumn (100 µm x 2 cm, 
C18, 5 µm, 100A, nanoViper) and a 20 cm long fused silica capillary column (75 µm ID) packed 
with Reprosil – Pur C18 AQ 3 µm reversed-phase material (Dr. Maisch, Ammerbuch-Entrigen, 
Germany). In the case of formerly N-sialylated and N-linked-deglycopeptides, the HPLC gradient 
was 0-28% solvent B (95% ACN 0.1% FA) in 60 min at a flow rate of 250 nl/min. In the case of 
mono and multi-phosphorylated peptides, the HPLC gradient was 1-35% solvent B (95% ACN 
0.1% FA) in 120 min at a flow rate of 250 nl/min. The mass spectrometer was operated in positive 
mode with a data dependent acquisition method (Top N, N = 12). A falcon tube with 5% ammonia 
solution was placed below the needle tip of the chromatographic column, located next to the orifice 
of the mass spectrometer to decrease the charge state of the ions and increase the HCD 
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fragmentation [45]. Briefly, MS scans (400-1400 m/z) were recorded at a resolution of 70,000. The 
automatic gain control (AGC) target for MS acquisitions was set to 1 × 10
6
 with a maximum ion 
injection time of 120 msec. Microscans were set to 1 for both the MS and MS/MS. Dynamic 
exclusion was set to 15 sec. Singly charged species were rejected. Analytes of two and higher 
charges were fragmented into the HCD collision cell with higher-energy collisional dissociation 
(HCD) with a normalized collision energy (NCE) set to 32. Subsequent MS/MS scans with a target 
value of 2 × 10
4
 ions were collected with a maximum injection time of 100 msec and a resolution of 
17,500. All MS and MS/MS spectra were obtained in profile mode. All raw data were viewed in 
Xcalibur v2.2 (Thermo Fisher Scientific).  
Data Analysis - The Proteome Discoverer software v.1.4.0.288 (Thermo Fisher Scientific) 
was used to perform database searching and peptide/protein relative quantification. The data were 
searched using MASCOT (v2.3, Matrix Science, London, UK) and Sequest HT (Thermo Fisher 
Scientific) as database searching engines with a Swiss-Prot v.3.53 human database (20, 243 entries) 
and the Uniprot human reference database (updated April 2014). Methionine oxidation, iTRAQ 
labeling (on peptide N-terminals and lysines), asparagine deamidation, serine, threonine and 
tyrosine phosphorylation were set as variable modifications, while cysteine carbamidomethylation 
was set as a fixed modification. Precursor mass tolerance was set to 10 ppm and MS/MS tolerance 
to 0.05 Da. During search, up to two missed cleavages were allowed. Data were filtered to a 1% 
false discovery rate using Proteome Discoverer’s Percolator function [46]. Peptide iTRAQ ratios 
were log2 transformed and normalized for the average to compensate for unequal amounts of 
digested and labeled protein samples in the sample mixture. Before submission to significance 
analysis, the modified peptides were normalized to the values of the corresponding proteins 
(Chapter 2). One tail heteroscedastic Student’s t-test (p-value < 5%) was used to assess statistical 
differences in peptide amount between conditions. Only putative glycosylation sites, which contain 
glycosylation sequon (NXS/T/C, X ≠ P), were further analyzed. Annotation and classification of the 
identified proteins were facilitated by using PANTHER Classification System 
(http://www.pantherdb.org/) [47]. Motif-X algorithm was used to predict the consensus 
phosphorylation site motifs. All the phosphopeptides were aligned, and their lengths were adjusted 
to ±12 aa from the central phosphorylation site position and submitted to the Motif-X software 
(http://motif-x.med.harvard.edu/) [48]; the IPI Human Proteome database was selected as 
background. The cutoff values were a minimum of 20 occurrences and a significance of p < 
0.000001. Logo-like representations were created to graphically display each identified motif. In 
addition, the adjusted 13 aa phosphopeptide sequences were searched against multiple known linear 
protein kinase motifs (http://www.phosida.com), to obtain the kinase motifs matched with high 
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probability [49]. Clustering analysis was performed by using Perseus (v. 1.5.0.15, tool of MaxQuant 
package). Literature mining of protein-protein interactions was carried out using STRING (v. 9.1) 
in action view at high settings (0.7) [50].   
3. RESULTS 
In this study we looked into the membrane proteome of PMPs with the aim of unveiling 
phosporylation and glycosylation sites. We applied quantitative proteomics to investigate modified 
peptide changes in PMPs obtained by differentially activated platelet samples (Fig.1). ADP, 
thrombin and collagen were used for platelet activation as known physiological agonists. Thrombin, 
which is constantly used to generate PMPs in vitro, was set as control. PMPs were first obtained 
from fresh apheresis platelet, lysed in presence of Na2CO3 [51], membrane enriched, iTRAQ 
labeled and subjected to phosphorylated and glycosylated peptide enrichments (Fig.2). Modified 
peptides were then purified or fractionated by HILIC and analyzed by nLC-MS/MS. All 
experiments were performed in biological triplicates. 
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Fig. 1 Experimental scheme for the quantitative phosphoproteomics and glycoproteomics 
comparison of PMPs obtained from differentially activated platelet samples  
Modified peptide identification and comparison analysis – A total of 1315 phosphopeptides 
including 1206 mono-phosphorylated peptides, 95 double phosphorylated peptides and 14 triple-
phosphorylated were found. In particular, a total of 1438 phosphorylation sites including 1161 
phospo-serine (pS), 205 phospho-threonine (pT) and 35 phospho-tyrosine (pY) were identified. 
After removing redundancy a total of 1225 unique phosphopeptides and 614 unique phospoproteins 
were identified (Fig. 3A). In the phosphopeptide fraction a total of 42 peptides were found to be 
significantly different in terms of relative abundance in the ADP induced MPs as compared to the 
control, which was thrombin stimulation. Thirteen proteins were significantly different in collagen 
induced activation and 26 peptides in thrombin and collagen co-stimulated MPs. A total of 1765 
peptides were identified in the N-sialylated fraction (Fig. 3A). In this fraction 54 peptides were 
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found to be significantly different in terms of relative abundance in the ADP induced MPs as 
compared to the control, which was thrombin activation. Twenty-two proteins were significantly 
different in collagen induced activation and 16 peptides in thrombin and collagen co-stimulated 
MPs. A total of 1166 peptides were found in the N-glycosylated fraction (Fig. 3A). In this fraction a 
total of 46 peptides were found to be significantly different in terms of relative abundance in the 
ADP induced MPs as compared to the control, which was thrombin stimulation. Seven-teen 
proteins were significantly different in collagen induced activation and 18 peptides in thrombin and 
collagen co-stimulated MPs. After removing redundancy between the glycosylated fractions, a total 
of 481 unique N-sialylated peptides were identified and assigned to 306 unique proteins and 241 
unique N-glycosylated peptides assigned to 187 proteins (Fig. 3B). Moreover, 523 peptides were 
identified in both of the glycosylated fractions and assigned to 234 proteins. In this work, a total of 
1245 unique glycosylated peptides were identified and assigned to 533 unique glycosylated 
proteins.  
 
Fig. 2 Experimental scheme of the enrichment strategies used for the quantitivative 
phosphoproteomics and glycoproteomics analysis of PMPs 
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Figure 3. A) Overview of the all identified peptides, unique modified peptides and unique modified 
proteins. B) Overlap between the glycopeptides found in the N-sialo and in the N-Glyco fraction 
Gene ontology analysis of the identified proteins – We next characterized the gene ontology 
of the identified proteins. Biological processes analysis showed that most of the proteins detected 
were involved in cellular and metabolic process (Fig. 4A). Molecular functions analysis underlined 
that the majority of proteins played roles in protein binding, catalytic and receptor activity (Fig. 
4B). Cellular component analysis highlighted that proteins were mostly associated with cell part and 
organelle. Protein class analysis displayed that proteins were mainly receptors and hydrolases 
(especially in the sialylated fraction), enzyme modulators and cytoskeletal proteins (especially in 
the phosphorylated fraction).  
Motif-X and kinase associated motif analysis - In order to identify possible phosphorylation 
and kinase related motifs in our phosphopeptide data, the frequency of particular amino acids in the 
proximity of phosphorylation sites was analyzed with the Motif-X software. Briefly, 9 putative 
motifs were identified, 2 of which were found to be associated to kinase motifs such as CAMKII 
(R-X-X-pS) and PKA (R-X-pS) (Fig. 4C). The identified motifs were only pS based motifs; this 
might be due to the low abundance of pT and pY compared to pS. 
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Fig. 4 GO analysis of the identified phosphoproteins, sialoproteins and glycoproteins showing A) 
Biological process and B) Molecular function. C) Motif-X and kinase associated motif analysis of 
the identified phosphopeptides 
Clustering and protein-protein interaction analysis of differentially abundant proteins 
between treatments- We next performed cluster analysis, considering the relative abundance of a 
protein in the three treatments as compared to control. We divided the trends of protein abundance 
into four clusters for the phosporylated, four clusters for the N-sialylated and five clusters for the N-
glycosylated fraction. Proteins belonging to the same cluster were subjected to STRING analysis to 
perform literature mining of protein-protein interactions and protein networks. Three major clusters 
were found to be associated to focal adhesion. A first cluster (Fig. 5A), containing 32 membrane 
phospoproteins mostly abundant in ADP induced microparticles (Fig. 5B), was enriched in proteins 
related to focal adhesion (Fig. 5C). A second cluster (Fig. 6A), including 66 membrane N-
sialoproteins that were mostly abundant in thrombin and collagen co-stimulated microparticles (Fig. 
6B), was enriched in proteins associated to focal adhesion (Fig. 6C) as well as a third cluster (Fig. 
7A), which contains 47 N-linked glycoproteins (Fig. 7B, 7C).  
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Fig. 5 A) Heat map representing log2 fold changes of the quantitative data (green-lowest abundance 
and red-highest abundance). B) Trends of the abundance of a specific cluster and C) protein-protein 
interaction analysis of the same cluster highlighting a protein network related to focal adhesion. 
Thicker, blue and black lines indicate more confident, binding and reaction associations, 
respectively. 
A B 
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Fig. 6 A) Heat map representing log2 fold changes of the quantitative data (green-lowest abundance 
and red-highest abundance). B) Trends of the abundance of a specific cluster and C) protein-protein 
interaction analysis of the same cluster highlighting a protein network related to focal adhesion. 
Thicker, blue and black lines indicate more confident, binding and reaction associations, 
respectively. 
Taken together, the list of modified proteins, that we identified and quantified, underlined many 
common function of phosporylated and glycosylated proteins in platelets as receptors for pledging 
adhesion to the subendothelial matrix and platelet-platelet cohesion [27], as motors for inside-out  
and outside-in signaling pathways [52] and as initiators for platelet activation [53]. In addition, we 
found a general enrichment of proteins implicated in cell-cell communication, which may confirm 
the role of microparticles as key components of the intercellular communication network [36]. 
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Fig. 7 A) Heat map representing log2 fold changes of the quantitative data (green-lowest abundance 
and red-highest abundance). B) Trends of the abundance of a specific cluster and C) protein-protein 
interaction analysis of the same cluster highlighting a protein network related to focal adhesion. 
Thicker, blue and black lines indicate more confident, binding and reaction associations, 
respectively. 
4. DISCUSSION 
In this work, we performed phosphoproteomics and glycoproteomics studies of PMPs obtained by 
differentially activated platelet samples. In order to reduce RBCs and leukocytes contaminations, 
apheresis platelets were used for PMPs generation. Activations were carried out using commonly 
known platelet physiological agonists following published procedures with minor modifications. An 
additional centrifugation step (1000 x g) was introduced to further purify PMPs from intact 
platelets. However, despite the supernatant was formed mainly by PMPs, we cannot exclude 
possible exosome contaminations in our samples. By treating with Na2CO3 [51], we separated and 
enriched membrane proteins, in which phosphorylated and glycosylated sites can normally be 
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found. Modified peptides were simultaneously enriched following published protocols with few 
modifications [38-41].   
Phosphorylation in PMPs - In this study, 1438 phosphorylation sites distributed on 1225 unique 
phosphopeptides were identified and assigned to 614 phosphoproteins. In particular, a total of 1161 
phosphoserine, 205 phosphothreonine and 35 phoshotyrosine were found. Despite the low 
abundance, the induction of tyrosine phosphorylation on relevant signaling molecules has emerged 
as a key event to stimulate signaling pathways that generate platelet activation [54]. Moreover, we 
found Talin-1, which was identified to be highly phosphorylated. Talin-1 was demonstrated to be 
post-translationally modified by phosphorylation upon platelet activation, its subcellular 
distribution can be regulated by its phosphorylation state [55]. Talin-1 is involved in platelet 
mediated processes as well as vasodilator-stimulated phosphoprotein, found to be phosphorylated in 
our study on Ser46,  in which phosphorylation on Ser157 was discovered to be related to platelet 
activation [56]. This protein was shown to interact with zyxin by building actin-rich structures [57]. 
Zyxin was found to be highly phosphorylated as well. Vinculin, in which phosphorylation on 
Tyr100 and Tyr1065 was shown to affect platelet spreading [58], was identified to be highly serine 
phosphorylated. Vinculin was recently identified to be a possible biomarker of atherosclerotic 
disease [59], which is a platelet activation mediated pathological process [60]. Fibrinogen alpha 
chain, found to be highly serine and threonine phosphorylated, was shown to be involved with 
integrins in platelet spreading and adhesion [61]. However, this protein was previously identified to 
be phosphorylated by casein kinases [62,63]. Beta-actin, found to be phosphorylated on Ser235, 
was identified to be critically required for the regulation platelet nitric oxide synthase 3 activity 
[64].  LIM domain and actin-binding protein 1, which is also deeply involved in platelet activation, 
was found to be serine phosphorylated as well. In particular, this proteins was demonstrated to 
participate in cofilin phosphorylation mechanisms during platelet shape change and secretion [65]. 
Moreover, cofilin-1, which was identified to be phosphorylated on Ser156, was shown to promote 
actin reorganization and phosphatidylserine exposure in platelets [66]. Cofilin-1 was also shown to 
be regulated by Rho-associated protein kinase 2, which is required for stabilizing actin cytoskeleton 
[67]. Rho-associated protein kinase 2 was found phosphorylated on Ser1132 and Thr1212.         
Glycosylation in PMPs – In this study, 481 unique peptides were found to be N-sialylated and 
assigned to 306 proteins (Fig. 8). Moreover, 241 unique peptides were identified to be N-
glycosylated and assigned to 187 proteins (Fig. 9). In particular, a total of 1245 unique glycosylated 
peptides were found and assigned to 533 unique glycosylated proteins. In addition, glycopeptides 
fractionation was used in order to decrase sample complexity and improve the identification (Fig. 
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\10). However, coagulation factor V, which participate as cofactor with factor Xa to activate 
prothrombin to thrombin, was found to be highly glycosylated such as on Asn297 that is close to 
thrombin cleavage site Arg334 [31]. In particular, its N-linked carbohydrate moieties was shown to 
play a key role in activated protein C-catalyzed cleavage and inactivation of coagulation factor V. 
[68]. Multimerin-1, which was shown to be associated to coagulation factor V and stored within a-
granules [69], was found to be heavily sialylated and glycosylated such as on Asn114, Asn120 and 
Asn344, Asn828, Asn1020 respectively.  After factor V activation, the multimerin 1-coagulation 
factor V protein complex were found to be dissociated, which may suggest a role of multimerin 1 in 
delivering and localizing factor V on platelets prior to prothrombinase assembly [70]. Multimerin-1 
was in vitro found to be an efficient ligand for several integrins such as integrin αIIbβ3 and integrin 
αVβ3 on activated platelets [71]. Von Willebrand factor was reported to contribute to platelet 
function by regulating the initiation and progression of thrombus formation at sites of vascular 
injury [72]. This proteins was identified to be heavily N-glycosylated such as on Asn1515, Asn1574 
and Asn2585.  
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Fig. 8 Protein-protein interaction in the N-sialylated proteins identified in this study showing two 
different network related to coagulation cascade (purple) and focal adhesion (green).  
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Fig. 9 Protein-protein interaction in the N-glycosylated proteins identified in this study showing a 
network related to focal adhesion (light blue). 
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Differentially expressed focal adhesion related proteins - Adhesion of cells to the 
extracellular matrix (focal adhesion) was shown to mediate several cellular functions such as 
morphology, migration, proliferation, survival, and differentiation [73]. These functions are 
essential during cellular development and for the maintenance of tissue architecture and the 
induction of tissue repair. Predominant receptors for the control of cell adhesion to the extracellular 
matrix are integrins [26,74]. As mentioned above, integrins are directly related to the platelet 
activation process. Our analysis revealed several differentially expressed modified peptides within 
focal adhesion related proteins and integrins. In addition, for the abundance of glycosylated 
significantly changed peptides in focal adhesion related proteins, we observed a decrease in the 
ADP and collagen induced MPs and an increase in the thrombin and collagen co-stimulated MPs. 
On the other hand, we found an increase in the ADP induced activation and a decrease in 
thrombin/collagen co-stimulated MPs in the phosphorylated significantly chaged sites. 
Interestingly, integrin αIIbβ3 showed 4 significantly changed modified peptides as compared to the 
control, which was thrombin stimulation. Integrin αIIbβ3 is involved in platelet activation and PMPs 
formation [24]. Integrin alpha-5, which showed 5 glycosylated changed sites as compared to the 
control, was found to be related to cell adhesion by N-glycosylation [75]. Integrin alpha-6, which 
contains a changed glycosylated site, was found to be involved in diverse platelet mediated 
processes such as adhesion, activation and arterial thrombosis. [76]. However, Integrin alpha-6 
receptor activity is related to glycosylation in cell-matrix interaction [77]. Filamin-A, which 
contains 4 significantly changed peptides, 3 of which were phosphorylated and 1 was glycosylated, 
was shown to be implicated in cytoskeletal rearrangements and cell shape changes, which are 
related to platelet activation [78]. Moreover, differences in the degree of filamin phosphorylation 
were also found after platelet activation [79]. Thrombospondin-1, which showed a significantly 
changed glycosylated site, was demonstrated to mediate cell-cell and cell-matrix interactions by 
binding several active molecules such as integrins, fibronectin, laminin, type V collagen [80] and to 
be highly glycosylated [31]. Vitronectin, which contains a significantly changed glycosylated site as 
well, was found to be implicated in platelet aggregation by interacting with activated platelets [81].  
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Fig. 10 HILIC chromatograms showing the fractionation of the sialopeptides respectively in the (A) 
first, second (B) and third (C) replicates. 
 
5. CONCLUSIONS 
In this work, the phosphoproteome and the glycoproteome of PMPs has been deeply investigated 
leading to the identification of 1225 unique phosphopeptides assigned to 614 phosphoproteins and 
to the identification of 1245 unique glycosylated peptides assigned to 533 unique glycoproteins. 
Our proteomics approach unveiled that glycosylation on focal adhesion related protein, in particular 
on integrins such as αIIbβ3, was directly related to the physiological agonist strength used for platelet 
activation. Collectively, our MS-based quantitative study provided an overview of the PTM-ome of 
PMPs, which can be of high interest to reveal biological insights about platelet response to stimuli. 
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6. APPENDIX 
 
Table 1. Dataset of significantly changed phoshoproteins 
 
ADP Collagen Thr.&Collagen Cluster Accessions 
-0.5961741 1.154494 -0.5583196 Cluster 1 Q05655 
-0.5790147 1.154699 -0.5756842 Cluster 1 O15439 
-0.6272953 1.153216 -0.525921 Cluster 1 Q8WWA1 
-0.6772734 1.14856 -0.4712865 Cluster 1 Q9NXH8 
-0.6539287 1.151151 -0.4972219 Cluster 1 Q8WWA1 
-0.7844507 1.126036 -0.3415852 Cluster 1 P02794 
-0.8447746 1.104125 -0.2593509 Cluster 1 O43294 
-0.9417709 1.049505 -0.1077342 Cluster 1 Q7LDG7 
-0.2340707 1.096274 -0.8622032 Cluster 1 Q9H4B7 
-0.2956866 1.114501 -0.8188144 Cluster 1 Q13884 
0.0763157 0.9596557 -1.035971 Cluster 1 Q9H4B7 
-1.120209 0.3175181 0.8026913 Cluster 2 Q5SQ64 
-1.110837 0.2824157 0.8284215 Cluster 2 Q9NTJ5 
-1.095715 0.2323309 0.8633838 Cluster 2 Q5T4S7 
-1.142475 0.4261051 0.7163697 Cluster 2 O95810 
-1.143032 0.4297151 0.7133173 Cluster 2 P61073 
-1.136602 0.391945 0.7446573 Cluster 2 Q9Y385 
-1.135654 0.3869497 0.7487048 Cluster 2 P51452 
-1.136056 0.38905 0.7470056 Cluster 2 Q9Y6X5 
-1.1547 0.5763887 0.5783113 Cluster 2 P21333 
-1.153429 0.5297903 0.6236383 Cluster 2 O95870 
-1.151748 0.5044125 0.6473358 Cluster 2 Q9H4B7 
-1.151748 0.5044125 0.6473358 Cluster 2 Q9H4B7 
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-1.149693 0.6678793 0.4818133 Cluster 2 Q8TC12 
-1.149693 0.6678793 0.4818133 Cluster 2 Q8TC12 
-1.151841 0.6462522 0.5055889 Cluster 2 P00488 
-1.075371 0.901942 0.173429 Cluster 2 O43149 
-1.05277 0.9371848 0.1155853 Cluster 2 Q7L576 
-1.114771 0.8180835 0.2966881 Cluster 2 P51149 
-1.132144 0.7627645 0.3693793 Cluster 2 P50552 
-1.055686 0.1226937 0.932992 Cluster 2 O95810 
-1.023478 0.048738 0.9747398 Cluster 2 P55072 
-1.021595 0.0446874 0.9769072 Cluster 2 P29350 
-1.021937 0.0454224 0.9765148 Cluster 2 O75558 
-0.9815561 -0.0359199 1.017476 Cluster 2 P17612 
-0.9485215 -0.0960288 1.04455 Cluster 2 Q86YW5 
-0.889893 -0.192288 1.082181 Cluster 2 Q86YW5 
-0.5544647 -0.5999374 1.154402 Cluster 2 Q13576 
-0.5465915 -0.6075722 1.154164 Cluster 2 P07359 
-0.4799636 -0.669538 1.149502 Cluster 2 P62491 
-0.4458545 -0.6995208 1.145375 Cluster 2 Q96C24 
-0.7564744 -0.3772824 1.133757 Cluster 2 P07359 
-0.665898 -0.4840178 1.149916 Cluster 2 P21333 
-0.7033418 -0.4414133 1.144755 Cluster 2 Q86YW5 
0.7928807 -1.123424 0.3305432 Cluster 3 Q9Y385 
0.5030736 -1.151641 0.6485675 Cluster 3 P10909 
0.0649006 -1.030869 0.9659689 Cluster 3 Q8N699 
0.0906364 -1.042233 0.9515964 Cluster 3 Q96AP7 
0.1477147 -1.065641 0.9179265 Cluster 3 O00161 
0.7198238 0.4220026 -1.141826 Cluster 4 Q9Y624 
0.8176042 0.2973441 -1.114948 Cluster 4 P08514 
0.7718096 0.3578912 -1.129701 Cluster 4 Q9H4B7 
0.8850541 0.1997419 -1.084796 Cluster 4 P04792 
0.8850541 0.1997419 -1.084796 Cluster 4 P04792 
0.8841661 0.2011026 -1.085269 Cluster 4 P08567 
0.9485448 0.0959881 -1.044533 Cluster 4 P21333 
0.9826832 0.0337777 -1.016461 Cluster 4 P05106 
0.9826832 0.0337777 -1.016461 Cluster 4 P05106 
1.046393 -0.1003532 -0.9460397 Cluster 4 Q9Y210 
1.057038 -0.1260226 -0.9310153 Cluster 4 Q9H4B7 
1.055927 -0.1232863 -0.9326407 Cluster 4 P16615 
1.086123 -0.2035714 -0.8825511 Cluster 4 P04792 
1.116326 -0.3025041 -0.8138223 Cluster 4 Q9Y210 
1.113385 -0.291588 -0.821797 Cluster 4 O15173 
1.082329 -0.8896226 -0.1927062 Cluster 4 P08567 
1.096624 -0.861461 -0.2351627 Cluster 4 P27105 
1.119025 -0.8061644 -0.3128607 Cluster 4 Q96RI0 
1.115565 -0.8159218 -0.2996434 Cluster 4 P07900 
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1.135045 -0.7512471 -0.3837978 Cluster 4 P04792 
1.135045 -0.7512471 -0.3837978 Cluster 4 P04792 
1.131985 -0.7633684 -0.3686168 Cluster 4 P20645 
1.126339 -0.783443 -0.3428959 Cluster 4 P07900 
1.154576 -0.5919492 -0.5626273 Cluster 4 O15439 
1.148404 -0.6784948 -0.4699087 Cluster 4 P07900 
1.150443 -0.6610183 -0.4894245 Cluster 4 O75791 
1.152833 -0.5195587 -0.6332738 Cluster 4 O00264 
1.149454 -0.4795059 -0.6699479 Cluster 4 O00264 
1.147222 -0.4599862 -0.6872362 Cluster 4 O15173 
1.146865 -0.4571369 -0.6897286 Cluster 4 Q9Y624 
1.143626 -0.4336475 -0.7099785 Cluster 4 P21796 
1.143626 -0.4336475 -0.7099785 Cluster 4 P21796 
 
Table 2. Dataset of significantly changed sialoproteins 
 
ADP Collagen Thr.&Collagen Cluster Accessions 
0.8669646 -1.093997 0.2270321 Cluster 1 P05106 
0.8669646 -1.093997 0.2270321 Cluster 1 P05106 
0.9658112 -1.030999 0.065188 Cluster 1 Q9HDC9 
1.078065 -0.1807975 -0.8972673 Cluster 2 Q86WI1 
1.125487 -0.3392278 -0.7862592 Cluster 2 P10909 
0.7879565 0.3370098 -1.124966 Cluster 2 P05556 
0.466007 0.6819436 -1.147951 Cluster 2 O95858 
0.5045524 0.6472071 -1.15176 Cluster 2 Q9Y210 
-1.154701 0.5776709 0.5770296 Cluster 3 Q6UX71 
-1.153916 0.5401104 0.6138059 Cluster 3 Q9Y2Q0 
-1.153121 0.5242693 0.6288514 Cluster 3 P08962 
-1.109707 0.2784234 0.8312832 Cluster 3 Q9Y274 
-1.124769 0.3361727 0.7885959 Cluster 3 P51575 
-1.129485 0.3569 0.7725846 Cluster 3 Q13201 
-1.133766 0.37733 0.7564363 Cluster 3 Q13201 
-1.137774 0.3982928 0.7394814 Cluster 3 P08575 
-0.9038765 -0.1703603 1.074237 Cluster 3 Q14766 
-0.9038765 -0.1703603 1.074237 Cluster 3 Q14766 
-0.9319314 -0.1244815 1.056413 Cluster 3 Q13201 
-0.9300988 -0.1275612 1.05766 Cluster 3 P08648 
-0.9254878 -0.1352562 1.060744 Cluster 3 P16284 
-0.9254878 -0.1352562 1.060744 Cluster 3 P16284 
-0.8801501 -0.2072285 1.087379 Cluster 3 P16284 
-0.8715028 -0.2202685 1.091771 Cluster 3 P11279 
-0.9905474 -0.0186446 1.009192 Cluster 3 Q9Y274 
-0.9692178 -0.0589559 1.028174 Cluster 3 Q13201 
-1.024289 0.0504908 0.9737982 Cluster 3 Q9Y274 
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-1.036452 0.0774027 0.9590494 Cluster 3 P08575 
-1.036452 0.0774027 0.9590494 Cluster 3 P08575 
-1.036452 0.0774027 0.9590494 Cluster 3 P08575 
-1.041275 0.0884226 0.9528524 Cluster 3 Q14766 
-1.055248 0.12162 0.9336277 Cluster 3 O15031 
-1.057923 0.1282131 0.9297099 Cluster 3 P07602 
-1.057032 0.1260077 0.9310241 Cluster 3 O15031 
-1.05687 0.1256086 0.9312615 Cluster 3 Q13201 
-1.057353 0.1268018 0.9305514 Cluster 3 Q13201 
-1.061054 0.1360368 0.9250176 Cluster 3 P01137 
-1.059451 0.1320155 0.9274352 Cluster 3 Q12913 
-1.071741 0.1636773 0.908064 Cluster 3 P08514 
-1.069477 0.1576927 0.9117846 Cluster 3 P16284 
-1.069544 0.157869 0.9116754 Cluster 3 P16284 
-1.075407 0.1735262 0.9018807 Cluster 3 P01137 
0.2651565 -1.105856 0.8406992 Cluster 3 P02679 
0.0211656 -1.010415 0.9892492 Cluster 3 Q9C0H2 
-0.2216313 -0.8705913 1.092223 Cluster 3 O60704 
-0.1951923 -0.8880128 1.083205 Cluster 3 P11279 
-0.1086421 -0.9412429 1.049885 Cluster 3 P21926 
-0.1606852 -0.9099277 1.070613 Cluster 3 Q9P126 
-0.1541864 -0.9139517 1.068138 Cluster 3 P34810 
-0.6709062 -0.4784348 1.149341 Cluster 3 P16284 
-0.6688158 -0.4807694 1.149585 Cluster 3 Q6UWL2 
-0.6688158 -0.4807694 1.149585 Cluster 3 Q6UWL2 
-0.8199301 -0.2941557 1.114086 Cluster 3 P08575 
-0.7908673 -0.333193 1.12406 Cluster 3 Q9C0H2 
-0.7640859 -0.36771 1.131796 Cluster 3 Q14766 
-0.7640859 -0.36771 1.131796 Cluster 3 Q14766 
-0.7546077 -0.3796145 1.134222 Cluster 3 P14625 
-0.7567936 -0.3768831 1.133677 Cluster 3 Q9NZ08 
-0.5159518 -0.6366443 1.152596 Cluster 3 P16284 
-0.479403 -0.67004 1.149443 Cluster 3 P14625 
-0.4938923 -0.6569636 1.150856 Cluster 3 O60704 
-0.4918929 -0.6587806 1.150674 Cluster 3 Q86WI1 
-0.5578957 -0.5965887 1.154484 Cluster 3 P07996 
-0.5578957 -0.5965887 1.154484 Cluster 3 P07996 
-0.550312 -0.6039729 1.154285 Cluster 3 P08575 
-0.5933443 -0.5612072 1.154552 Cluster 3 Q92542 
-0.5933443 -0.5612072 1.154552 Cluster 3 Q92542 
-0.4245703 -0.7176638 1.142234 Cluster 3 Q92542 
-0.4073716 -0.7320152 1.139387 Cluster 3 P21731 
-0.4073716 -0.7320152 1.139387 Cluster 3 P21731 
-0.3987146 -0.7391362 1.137851 Cluster 3 Q10588 
-0.3302462 -0.7931061 1.123352 Cluster 3 P04004 
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-0.2872919 -0.8249084 1.1122 Cluster 3 Q13201 
-0.2816584 -0.8289653 1.110624 Cluster 3 P07602 
-0.2551104 1.102844 -0.847734 Cluster 4 Q12907 
-1.147365 0.6862228 0.4611421 Cluster 4 Q86WI1 
-1.140792 0.7251367 0.4156556 Cluster 4 Q86WI1 
-1.118906 0.8065102 0.3123956 Cluster 4 Q13201 
-1.114473 0.8188908 0.2955818 Cluster 4 P13598 
-1.075536 0.9016591 0.1738769 Cluster 4 Q9BVK6 
-1.015513 0.9837292 0.0317837 Cluster 4 P08195 
-1.006891 0.992963 0.0139285 Cluster 4 P40238 
-1.03979 0.9547829 0.0850071 Cluster 4 P42892 
-0.7227056 1.141271 -0.4185654 Cluster 4 P20645 
-0.6452975 1.151922 -0.506624 Cluster 4 P13473 
-0.5139806 1.152461 -0.6384805 Cluster 4 Q6UX71 
-0.8752056 1.089915 -0.2147095 Cluster 4 P42892 
-0.897352 1.078017 -0.1806645 Cluster 4 O14672 
-0.9249661 1.061088 -0.1361223 Cluster 4 Q15904 
-0.8325872 1.109185 -0.276598 Cluster 4 O14672 
-0.7946767 1.12285 -0.328173 Cluster 4 O95858 
-0.808507 1.118212 -0.3097054 Cluster 4 P10909 
 
 
Table 3. Dataset of significantly changed N-glycoproteins 
 
ADP Collagen Thr.&Collagen Cluster Accessions 
-1.024631 0.0512317 0.9733995 Cluster 1 P16284 
-1.056329 0.124274 0.9320546 Cluster 1 P08575 
-1.043049 0.0925285 0.95052 Cluster 1 Q12913 
-1.046509 0.1006259 0.9458827 Cluster 1 O15031 
-1.047461 0.1028757 0.9445855 Cluster 1 Q86WI1 
-0.9512662 -0.0912174 1.042484 Cluster 1 Q9NV96 
-0.9710989 -0.0554914 1.02659 Cluster 1 P21333 
-0.984266 -0.0307583 1.015024 Cluster 1 Q9UIQ6 
-0.9916688 -0.0164592 1.008128 Cluster 1 P16109 
-0.9921586 -0.0155025 1.007661 Cluster 1 P23229 
-1.131449 0.3660571 0.7653921 Cluster 1 Q9C0H2 
-1.138272 0.4010491 0.7372226 Cluster 1 Q9Y4L1 
-1.084216 0.1980779 0.8861381 Cluster 1 P08575 
-1.086278 0.2040216 0.8822561 Cluster 1 P14625 
-1.093756 0.2262943 0.8674614 Cluster 1 Q9NV96 
-1.073625 0.1687124 0.9049122 Cluster 1 Q9H7M9 
-1.075378 0.1734481 0.90193 Cluster 1 Q9H7M9 
-1.122861 0.328221 0.7946404 Cluster 1 Q9Y251 
-1.104269 0.2598279 0.8444408 Cluster 1 Q9Y274 
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-1.107779 0.2717192 0.8360593 Cluster 1 P51575 
-1.1094 0.2773502 0.8320503 Cluster 1 Q9BVK6 
-1.110226 0.2802512 0.8299747 Cluster 1 Q92542 
-1.110226 0.2802512 0.8299747 Cluster 1 Q92542 
-1.112609 0.2887688 0.8238405 Cluster 1 Q96AP7 
-0.8006408 -0.3202563 1.120897 Cluster 1 P08575 
-0.8088363 -0.309261 1.118097 Cluster 1 Q08722 
-0.8161944 -0.2992713 1.115466 Cluster 1 P16284 
-0.8444408 -0.2598279 1.104269 Cluster 1 P08648 
-0.8444408 -0.2598279 1.104269 Cluster 1 P08648 
-0.8401878 -0.2658822 1.10607 Cluster 1 Q9C0H2 
-0.8344417 -0.2739957 1.108437 Cluster 1 P08648 
-0.8353217 -0.272758 1.10808 Cluster 1 Q92542 
-0.9095055 -0.1613639 1.070869 Cluster 1 P08575 
-0.8980265 -0.1796053 1.077632 Cluster 1 Q9NX62 
-0.8918919 -0.1891892 1.081081 Cluster 1 P08575 
-0.8926979 -0.1879364 1.080634 Cluster 1 P11279 
-1.124314 0.7900583 0.3342554 Cluster 1 Q9H4B7 
-1.127468 0.7796321 0.3478358 Cluster 1 Q14766 
-1.142182 0.7179429 0.424239 Cluster 1 Q12907 
-1.142182 0.7179429 0.424239 Cluster 1 Q12907 
-1.141822 0.7198446 0.4219779 Cluster 1 Q12907 
-1.154008 0.5423838 0.6116245 Cluster 1 P02671 
-1.154701 0.5773503 0.5773503 Cluster 1 P08514 
-1.149507 0.4800138 0.669493 Cluster 1 Q12913 
-1.150205 0.4869481 0.6632569 Cluster 1 Q9Y251 
-1.150205 0.4869481 0.6632569 Cluster 1 Q9Y251 
-1.024631 0.9733995 0.0512315 Cluster 1 P08648 
0.1227572 -1.055712 0.9329544 Cluster 2 Q9NXL6 
-0.2434013 -0.8558304 1.099232 Cluster 2 P08514 
-0.2598279 -0.8444408 1.104269 Cluster 2 Q14392 
-0.5619564 -0.5926085 1.154565 Cluster 2 P16284 
-0.5947547 -0.5597692 1.154524 Cluster 2 P16284 
1.15208 -0.6433695 -0.5087108 Cluster 3 Q13201 
1.115244 -0.8167987 -0.2984457 Cluster 3 Q969V3 
0.8579978 -1.098237 0.2402394 Cluster 3 Q13201 
0.8579978 -1.098237 0.2402394 Cluster 3 Q13201 
0.9832103 -1.015984 0.0327737 Cluster 3 P16278 
0.9832103 -1.015984 0.0327737 Cluster 3 P16278 
0.6692498 -1.149535 0.4802852 Cluster 3 Q92542 
0.6993029 -1.14541 0.446107 Cluster 3 P01009 
-0.6999132 1.145313 -0.4453994 Cluster 4 Q6UWL2 
-0.7258663 1.140647 -0.4147806 Cluster 4 Q13201 
0.1122858 0.9391178 -1.051404 Cluster 4 Q96K49 
0.0323497 0.9834327 -1.015782 Cluster 4 P08648 
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-0.1362954 1.061157 -0.9248617 Cluster 4 P40197 
-0.2402394 1.098237 -0.8579978 Cluster 4 P17301 
-0.2773501 1.1094 -0.8320503 Cluster 4 Q9Y6C2 
-0.3307704 1.123479 -0.7927083 Cluster 4 P40197 
-0.3307704 1.123479 -0.7927083 Cluster 4 P40197 
-0.3636976 1.13095 -0.7672524 Cluster 4 P10909 
0.3601721 0.7700229 -1.130195 Cluster 5 P16109 
0.5145079 0.6379898 -1.152498 Cluster 5 P20645 
1.077632 -0.1796053 -0.8980265 Cluster 5 Q13201 
1.089008 -0.2120192 -0.8769888 Cluster 5 P16671 
0.708361 0.4355464 -1.143907 Cluster 5 P05106 
0.6725134 0.4766359 -1.149149 Cluster 5 P13473 
0.9523641 0.0892841 -1.041648 Cluster 5 P40238 
0.9250203 0.1360324 -1.061053 Cluster 5 Q6UX71 
0.9049123 0.1687124 -1.073625 Cluster 5 Q9NXH8 
0.8108485 0.3065403 -1.117389 Cluster 5 P05556 
0.8510645 0.250313 -1.101378 Cluster 5 P13598 
 
 
 
 
 
 
 
 
 
 
 105 
 
 
 
 
 
 
 
4. The targeted way 
 
 
 
 
 
 
 
 
 
 
 
 106 
 
ABSTRACT 
 
Different sample treatment protocols for the liquid chromatography-electrospray-tandem mass 
spectrometry (LC-ESI-MS/MS) analysis of potential residuals of ovalbumin and caseins added to 
red wines were developed. In particular, attention was paid to the simultaneous detection and 
quantitation of fining agent residues, i.e. ovalbumin, - and -casein, in wine samples. The 
different sample treatment methods were compared in terms of protein recovery. The use of 
denaturing agents combined with size exclusion concentration and purification allowed to obtain a 
reproducible (RDS < 20%) analytical protocol with good recoveries (73(±2)-109(±4)% range) for 
digested proteins from 12.5 mL of wine sample. Matrix-matched calibration from LC-ESI-MS/MS 
analysis indicated that the devised method allowed detection of target peptides in the 0.01-0.8 
mg/mL range. Finally, method applicability and selectivity were demonstrated by using fining 
agents commonly exploited in winery industry and by analyzing 20 commercial red wine samples. 
 
1. INTRODUCTION 
 
The liquid chromatography-electrospray-tandem mass spectrometry (LC-ESI-MS/MS) 
determination of hidden allergens in foods is becoming of relevant importance because of the 
several advantages offered by this technique, including multi-tag detection, unambiguous allergen 
identification and accurate quantitative data [1,2]. The experimental workflow is generally based on 
the selection of targeted peptides and the use of selected reaction monitoring (SRM) acquisition 
mode for quantitative purposes [3-7]. Basically, quality of the final analytical results is based on the 
sample preparation procedure, the performance of the whole analytical method and the selection of 
a suitable calibration mode. Different sample treatment methods have been proposed as a function 
of the investigated food matrices and protein allergens [8-11], representing a crucial step of the 
whole procedure. The sample preparation method is usually performed manually and it is expected 
to extract and purify the compounds of interest in an easy, quantitative and reproducible manner. In 
this study our attention was focused on the LC-MS/MS analysis of potential residuals allergens in 
red wine. The organoleptic, antioxidants and anti-inflammatory properties of the red wine 
constituents are widely investigated and known. Red wine is an extremely complex matrix rich in 
polyphenols, tannins, anthocyanins and other molecules that can easily interact with proteins 
making challenging their quantitative analysis [10,12,13]. Recently, attention was paid to the 
putative presence of traces of exogenous proteins (i.e. caseins, albumins, lysozyme, gluten) added 
during wine fining process and removed before bottling. These proteins present allergen activity 
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and the accurate determination of their residual concentration level is desiderable to ensure 
consumer safety. Different analytical methods were proposed in the literature for quantitative 
purposes based both on immunoassay and mass spectrometry techniques [7,14-24]. Immunoassays 
present unique advantages of simplicity and fastness, but they are usually performed on a single 
target and mainly suffer of cross-reactivity reactions and poor accuracy. In this work, an LC-
MS/MS method for the simultaneous determination of ovalbumin, - and -casein in red wine is 
proposed. Different sample treatments for the detection of allergen residues in wine were evaluated 
and compared in terms of protein recovery. Generally, the investigated processes involved the use 
of cut-off filters, denaturing agents, protein precipitation or size-exclusion purification cartridges. 
Finally, by using the most suitable and efficient sample treatment protocol, the LC-MS/MS method 
was validated and applied to commercial fining agents and red wine samples. 
 
2. MATERIALS AND METHODS 
 
Chemicals - Urea (99.8%, purity) and thiourea were purchased from Carlo Erba (Milan, Italy). 
Acetonitrile (HPLC purity), formic acid (analytical reagent grade), trifluoroacetic acid (TFA, >98% 
purity), sodium dodecyl sulfate (SDS, 99% purity), trichloroacetic acid (TCA, >99% purity), 
ammonium hydrogen carbonate (99% purity), trypsin from bovine pancreas, iodoacetamide (IAM, 
>99% purity), DL-dithiothreitol (DTT, > 99% purity), a-casein, b-casein, ovalbumin and Bradford 
reagent were from Sigma-Aldrich (St. Louis, Missouri, USA). Potassium caseinate (Protoclar
®
) and 
egg-white powder were purchased from a local enological store. Buffered solutions and mobile 
phases were obtained in HPLC-grade water prepared with a Milli-Q element A10 System (S. 
Francisco, CA, USA). A total of 20 Italian commercial red still wine samples from different wine-
producing regions and brands were purchased from local stores. The investigated wines were 
produced during 2007-2011 vintages (Table 1). 
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Table 1. List of the analyzed red wine samples. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bioinformatic analysis - For each targeted protein, peptides providing good ESI sensitivity 
and unequivocally identifying the target protein were selected. Thereby, a tryptic digest of a 
standard mixture of the three proteins (200 mg/mL) in NH4HCO3 50 mM pH 8 was analyzed by 
LC-MS/MS under data-dependent acquisition (DDA). Using this acquisition mode, the ion-trap was 
programmed to ignore any singly charged species acquired in the 300-1200 amu mass range and to 
perform MS/MS analysis (normalized collision energy: 30) only on eluting species that overcome a 
predefined threshold of 500 cps. For each protein two marker peptides were selected (Table 2), 
considering different criteria such as quality of product ion spectra matches (Bioworks 3.3 database 
searching software, Thermo Electron Corporation, Marietta, Ohio) signal intensity of the most 
abundant product ion of MS/MS spectrum, no post translational modification sites and sequence 
specificity (BLAST search; algorithm: blastp; MATRIX PAM 30; GAP COSTS: existence 10, 
extension 1; DATABASE: non-redundant protein sequences). 
Sample N. 
Red wine 
sample 
Production 
Italian region 
Vintage 
1 Barbera Piemonte 2010 
2 Bonarda Emilia Romagna 2010 
3 Cannonau Sardegna 2009 
4 Cannonau Sardegna 2010 
5 Lambrusco Emilia Romagna 2010 
6 Lambrusco Emila Romagna 2011 
7 Lambrusco Emilia Romagna 2011 
8 Magliocco Calabria 2009 
9 Magliocco Calabria 2011 
10 Magliocco Calabria 2011 
11 Mamertino Sicilia 2009 
12 Montepulciano Abruzzo 2011 
13 Nebbiolo Piemonte 2010 
14 Nebbiolo Piemonte 2011 
15 Nero d'Avola Sicilia 2007 
16 Nero d'Avola Sicilia 2008 
17 Nero d'Avola Sicilia 2009 
18 Sangiovese Emilia Romagna 2007 
19 Syrah Sicilia 2008 
20 Syrah Sicilia 2009 
 109 
 
 
Table 2. SRM transitions monitored for the target peptides from the allergen proteins investigated 
 
Protein 
Precursor ion sequence 
(m/z; charge state) 
Product ion sequence 
(m/z; charge state; fragment type) 
α-casein 
HQGLPQEVLNENLLR 
(m/z 587.2; +3) 
HQGLPQEVLNENLL 
(m/z 793.6; +2; b14
+2
)
a
 
HQGLPQEV 
(m/z 445.2; +2; b8
+2
) 
YLGYLEQLLR 
(m/z 634.8; +2) 
GYLEQLLR 
(m/z 991.8; +1; y8
+1
)
a,b
 
LEQLLR 
(m/z 771.4; +1; y6
+1
) 
β-casein 
VLPVPQK 
(m/z 390.9; +2) 
PVPQK 
(m/z 568.4; +1; y5
+1
)
a
 
PVPQK 
(m/z 284.6; +2; y5
+2
) 
AVPYPQR 
(m/z 415.9; +2) 
PYPQR 
(m/z 330.6; +2; y5
+2
)
a,b
 
PYPQR 
(m/z 660.4; +1; y5
+1
) 
ovalbumin 
GGLEPINFQTAADQAR 
(m/z 844.9; +2) 
PINFQTAADQAR 
(m/z 666.3; +2; y12
+2
)
a,b
 
PINFQTAADQAR 
(m/z 1331.7; +1; y12
+1
) 
VASMASEK 
(m/z 411.9; +2) 
VASMASEK 
(m/z 402.8; +2; water loss)
a
 
SMASEK 
(m/z 652.2; +1; y6
+1
) 
a Most intense MS/MS transition 
b m/z transition monitored for the calculation of the validation parameters 
 
Sample treatment - A volume of 12.5 mL of red wine sample was fortified with the three 
proteins at different amounts and the mixture was homogenized before sample treatment. Five 
different sample treatments were investigated (procedure 1-5). In procedure 1 the sample was 
centrifuged at 7000 rpm for 150 min in ultrafiltration tube with 5 kDa cut-off membrane (Sartorius 
Stedim Biotech, Goettingen, Germany), previously conditioned with distilled water, to obtain a 
concentrated final volume of 2.5 mL. Afterward, protein precipitation was performed by diluting 
the sample (1:8 ratio) with ethanol/TCA (15%, w/v) and keeping in ice for 2 h. The solution was 
centrifuged at 9000 rpm for 10 min at 4°C. The pellet was then washed with ethanol and solubilized 
in 1mL NH4HCO3 50mM to pH 8. Tryptic digestion of wine extracts was performed after protein 
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reduction and alkylation. Reduction was performed by addition of DDT to a final concentration of 
10 mM and incubating the mixture at 30°C for 40 min. For alkylation reaction IAA was added to a 
final concentration of 20 mM and the mixture was left for 40 min in the dark; then DTT was added 
to have a final concentration of 10 mM. In the final step, enzymatic digestion was performed by 
adding a trypsin solution (0.5 mg/mL, in NH4HCO3 50 mM pH 8) to the sample in order to obtain a 
trypsin:protein ratio 1:50 and incubating overnight at 37°C. Ultimately, formic acid (1%, v/v) was 
added to quench the digestion reaction before LC-ESI-MS/MS analysis. In the second approach 
(procedure 2), a treatment with urea (final concentration 6M), thiourea (final concentration 2 M) 
and SDS (0.2% w/v) heating in boiling water for 10 min, was performed just before the cut-off 
concentration step, in order to obtain proteins free from interactions with other wine components, 
i.e. tannins, anthocyanins, polyphenols, etc. Afterward, the sample was diluted to 5 mL with 
NH4HCO3 50 mM at pH 8, then it was reduced, alkylated and digested as reported in the procedure 
1. The tryptic digest was then purified on a C18 SPE cartridge as follows: conditioning (2 mL 
methanol followed by 2 mL water), sample loading (5 mL), washing (water/methanol/TFA, 
89.9/10/0.1 v/v/v) and final elution (1 mL water/acetonitrile/TFA, 29.9/70/0.1, v/v/v). According to 
procedure 3, the addition of urea, thiourea, SDS denaturants and sample heating were carried out 
after centrifugation in ultrafiltration tubes. Then, the obtained 2.5 mL of sample was loaded onto a 
polyvinylpolypyrrolidone (PVPP)-based cartridge (Thermo Fisher Scientific, San Jose, CA, USA) 
to remove the phenolic compounds. NH4HCO3 was added to the extract to reach pH 8 and the 
reduction, alkylation and tryptic digestion were performed as reported in the procedure 1. Procedure 
4 differs from the previous one by the fact that the purification on PVPP cartridges was performed 
on tryptic digest, thus after reduction, alkylation and tryptic digestion reactions. Finally, procedure 
5 substitutes the use of PVPP cartridges in the procedure 3 with a size exclusion (SE)-based 
purification. Denaturation and heating steps were carried out on the concentrated samples before 
reduction and alkylation reactions. Then, a 100 mL aliquot was purified on a 6 kDa-size exclusion 
column Bio-Spin 6 (Bio-Rad Laboratories, Milan, Italy) as follows: conditioning for three times 
with 500 mL NH4HCO3 50 mM pH 8, loading 100 mL of sample, and eluting by centrifugation at 
1000 rpm for 4 min to collect the extract. The tryptic digestion was thus performed as described in 
the procedure 1. To assess recovery, a blank matrix and a wine matrix fortified with ovalbumin, - 
and -casein at two different concentration levels (10 and 100 mg/mL, five independent extractions 
for each level) were considered. 
Liquid chromatography-tandem mass spectrometry - All LC-MS/MS analyses were 
performed on a Surveyor LC system (Thermo Fisher Scientific, San Jose, CA) coupled online with 
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a LTQ linear ion trap (LIT) (Thermo Fisher Scientific). The system was controlled by the Xcalibur 
software. LC separation was performed by using a 100 mm x 2.1 mm, i.d. 2.7 mm, Kinetex C18 
column (Phenomenex, CA, USA) thermostated at 25 °C. A binary solvent gradient was used for the 
analysis of the tryptic digests; solvent A consisted of 0.1% (v/v) formic acid aqueous solution and 
solvent B was 0.08% (v/v) formic acid in acetonitrile. Following analytical column equilibration, 
each sample was loaded (30 mL) and eluted at a constant flow rate of 200 mL/min under the 
following optimized gradient: solvent B was initially set at 10% for 1 min, then delivered by a 
linear gradient from 10% to 60% in 15 min and to 95% in 2 min, then 2 min at 10% before column 
re-equilibration (5 min) for the next sample injection. Mass spectrometric conditions were set as 
follows: electrospray voltage, 3.5 kV; sheath gas, auxiliary gas and sweep gas set to 50, 20 and 5 
arbitrary units, respectively; capillary temperature, 200°C; capillary voltage, 20 V; tube lens 100 V. 
The mass spectrometer was operated in time-scheduled “Product Ion Scan mode” and, for 
quantitative purposes, in Selected Reaction Monitoring (SRM) acquisition mode, by monitoring the 
MS/MS transitions of the peptides VLPVPQK, AVPYPQR and VASMASEK from 0 to 5.50 min 
(segment 1), the transitions of the peptides HQGLPQEVLNENLLR and GGLEPINFQTAADQAR 
from 5.50 to 8 min (segment 2), and those of the peptide YLGYLEQLLR from 8 to 25 min 
(segment 3). The precursor ion-product ion SRM transitions monitored for each peptide are reported 
in Table 2. The normalized collision energy was set to 30 for all peptides. 
Method validation - Validation of the whole analytical method was performed according to 
Eurachem guidelines [25] on non commercial red wine subjected to fining process not involving the 
exploitation of the proteins under investigation. Sample treatment protocol was carried out using the 
procedure 5. As for the blank matrix, the absence of the proteins under investigation was previously 
verified. For this purpose, wine blank matrix was fortified with different amounts of standard 
proteins before sample treatment and measurements were carried out by monitoring the most 
abundant MS/MS transition for the peptide providing the best sensitivity for each protein (Table 2). 
The second peptide was used for confirmatory purposes. The detection (LOD) and quantification 
(LOQ) limits were calculated on matrix and were expressed as the concentration of analyte giving a 
signal that is 3s and 10s above the mean blank signal, respectively, where s is the standard deviation 
of the blank signal obtained from ten independent blank measurements. In particular, in order to 
assess the blank signal distribution, analytes were added before extraction, each in the amount 
proper to give the minimum integrable signal. Linearity was investigated starting from LOQ values 
of each peptide to 200 mg/mL (seven concentration levels, two replicates for each level and two 
injections for each extract). Mandel’s fitting test was performed to check linearity. The significance 
of the intercept ( = 0.05) was established by running a t-test. Accuracy was assessed in terms of 
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precision and trueness. Precision was calculated as RSD% in terms of intra-day repeatability and 
intermediate precision on three concentration levels (LOQ value for each protein, 10 and 100 
mg/mL), performing three independent replicates at each level and three LC-MS/MS injections for 
each extract. The intermediate precision was estimated over three days verifying homoscedasticity 
of the data and performing the analysis of variance (ANOVA) at the confidence level of 95%. 
Matrix effect was assessed by a t-test (α =  0.05, two- tailed) between curve slopes calculated on 
matrix tryptic digest and on aqueous tryptic digest. Trueness was measured in terms of percent 
recovery on two concentration levels, i.e. LOQ of each peptide and 50 mg protein/mL matrix, by 
calculating the ratio of determined and added protein content.  
3. RESULTS AND DISCUSSION 
For method development, marker peptides were firstly selected, then their chromatographic 
separation was optimized, and finally different sample treatment procedures were investigated. 
Validation was carried out on the final selected analytical procedure. 
Selection of the biomarker peptides and development of the LC-MS/MS method - The feature 
of this quantitative approach is the selection of the marker peptide ions, the evaluation of their CID 
fragmentation profile and the selection of intense and characteristic SRM transitions. As for 
biomarker peptide selection, different criteria were used. The selected proteins were identified with 
a sequence coverage average of ∼75%. Transitions for SRM analysis were carefully selected by 
varying normalized collision energy (from 20 to 35) for each peptide. The definitive assay was 
performed using a series of transitions (precursor/fragment ion pairs) as reported in Table 2. As for 
chromatographic separation, the elution gradient was set up in order to obtain a suitable separation 
among peptides within 10 min (Fig. 1). SRM signals were acquired on three different time windows 
in order to improve LIT ion sampling and thus instrumental repeatability with complex mixtures. 
Comparison of sample treatment procedures - Protein recovery was used as indication of the 
efficiency of the sample treatment procedure. By following the procedure 1 on five independent 
samples, recoveries lower than 5% and very low repeatability were observed (RSD > 60%). These 
findings could be explained on the basis of interactions between proteins and polyphenols, tannins 
and other matrix compounds that can interfere with both the protein precipitation and the tryptic 
digestion efficiency. In addition, strong ESI-MS signal suppression was observed. On the basis of 
these findings, initially, three commonly used denaturing agents (urea, thiourea and SDS) were 
added to the red wine samples in order to obtain proteins free from interaction with the matrix 
components. The use of 5 kDa cut-off filter for concentration purposes allowed to obtain extracts 
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with a reduced red color, suggesting a more effective separation between high-molecular weight 
compounds and small matrix interferents. Tryptic digestion was performed and peptides were 
purified on a C18 SPE cartridge with the final aim to reduce components that may cause ESI 
suppression. However, recovery values were lower than 10%. The protein colorimetric Bradford 
assay, performed after the cut-off filter step, demonstrated that the addition of the denaturing agents 
before this step cause a significant loss of total proteins (> 70%). This finding could be accordable 
to protein denaturation that reduces protein solubility due to the exposition of the hydrophobic sites. 
For this reason, proteins may precipitate on the filter membrane making very difficult their 
recovery. In order to avoid protein loss, the denaturing agents were added after centrifugation on the 
cut-off filter. The purification of the protein fraction from the phenolic compounds was carried out 
by using a PVPP cartridge. This kind of support, which is widely used for purification of red wine 
samples, it was used by following a standard protocol suggested by the providers. Tryptic digestion 
performed after purification on the PVPP cartridges provided recovery values significantly 
improved for both -casein (46±10%) and ovalbumin (181±32%), whereas in the case of -casein 
no signal was observed. A possible explanation could lie in the interaction or sticking of this protein 
on the PVPP support. When performing the tryptic digestion before PVPP treatment (procedure 4), 
no signals were observed for all the peptides suggesting the complete loss during the purification 
step. Finally, a size exclusion purification-based procedure was carried out on reduced and 
alkylated proteins, just before tryptic digestion. In this case, good recovery and RSD values were 
obtained for all proteins (ovalbumin 73±2%; -casein 99±5%; -casein 109±4%). After 
examination of the feasibility of the SPE, PVPP, and SE-based purification procedures for allergen 
clean-up, SE procedure was proved useful in eliminating time-consuming SPE process while 
maintaining the advantages of sample clean-up. In comparison with the conventionally used PVPP 
cartridges, the SE-based purification approach allowed to eliminate the phenolic compounds and 
denaturant agents without loss of proteins. The SE-based procedure provided the best performances 
in terms of recovery and precision. Reliability of the whole analytical procedure was thus 
demonstrated through validation and application to real samples. 
Method validation - Method validation was carried out in terms of limits of detection and 
quantification, linear dynamic ranges and accuracy. Considering the complexity of the matrix, good 
results in terms of sensitivity were obtained, LODs and LOQs ranging from 0.01 to 0.8 mg 
protein/mL wine and from 0.03 to 2 mg protein/mL, respectively (Table 3). Linearity of the method 
was proved by matrix-matched calibration over two orders of magnitude for -casein and 
ovalbumin and over three orders for -casein (r2 > 0.987, n = 20). Linearity was demonstrated by 
 114 
 
variance homogeneity assessment (p > 0.05) and by applying the Mandel fitting test after 
calculation of linear curve equations for targeted peptide; p values greater than 0.01 allowed to 
confirm that the quadratic model was not significantly better than the linear one. As for method 
precision, good results were achieved both in terms of intra-day repeatability and intermediate 
precision with RSD always lower than 10% and 19%, respectively. As for intermediate precision, 
ANOVA performed on the data acquired over three days showed that the mean values were not 
significantly different (p > 0.05). To verify matrix effect, the presence of systematic proportional 
errors were investigated with a t-test by comparing calibration curve slopes obtained for the 
aqueous tryptic digests and the matrix tryptic digests. Significant signal enhancement of 67% for 
the AVPYPQR peptide was obtained, whereas significant ion suppression of 15 and 38% for the 
YLGYLEQLLR and GGLEPINFQTAADQAR peptides, respectively, were calculated. Thus, 
matrix effect was overcome by performing a label-free quantification using calibration curves built 
on matrix tryptic digests. Trueness values from 82(±3) to 105(±3)% were also calculated. 
Table 3. Matrix-matched calibration curves, LOD and LOQ values of the targeted peptides 
obtained by using sample procedure 5 and SRM LC-ESI-MS/MS analysis. 
 
 
Method application - After validation, method suitability for the determination of allergenic 
proteins residues in red wine samples was investigated using two commercial fining agents, i.e. 
Protoclar® (i.e. potassium caseinate) and egg-white powder, commonly exploited in winery 
industry. Taking into account the complex composition of commercial fining powders, limits for 
their detection in red wine were also assessed; a LOD value of 0.2 mg/mL was calculated for 
Protoclar®, obtained by monitoring the m/z 415.9/m/z 330.6 MS/MS transition of the peptide 
AVPYPQR of -casein; a value of 1.6 mg/mL was calculated as LOD for egg-white powder, using 
the m/z 844.9/m/z 666.3 MS/MS transition of the peptide GGLEPINFQTAADQAR of ovalbumin. 
At 2.5 mg/mL concentration level of Protoclar® also -casein was detected. In Fig. 1 is reported the 
Protein 
LOD 
(µg/mL) 
LOQ 
(µg/mL) 
Linear range 
(µg/mL) 
Calibration curve 
y=a(±sa)x+b(±sb) 
r
2
 (n) 
α-Casein 0.5 1 LOQ – 100 
y = (58208 ± 1183)x  - 
(5208 ± 525) 
0.997 (20) 
β-Casein 0.01 0.03 LOQ – 50 y = (21684 ± 346)x 0.997 (20) 
Ovalbumin 0.8 2 LOQ – 100 
y = (39768 ± 1860)x - 
(4419 ±827) 
0.987 (20) 
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chromatogram for the analysis of a blank red wine sample fortified with the investigated 
commercial fining powders at 2.5 mg/mL, verifying the possibility of monitoring the SRM 
transitions selected for standard proteins and proving the applicability of the developed method for 
the analysis of red wine samples treated with commercial fining agents. The devised method was 
then applied to test method selectivity and to investigate the presence of allergenic fining residues 
in 20 commercial red wine samples. As the marker peptides are unique for each protein, false 
positive allergen detection is dramatically reduced. In accordance with the results of Restani et al. 
[21], no traces of the investigated fining agents were found in the samples, thus excluding any risk 
for allergic sensitive people, consistent with current European legislation [26-28]. Finally, method 
reliability was further proved by spiking all the investigated commercial red wine samples with -, 
- casein and ovalbumin at concentration levels corresponding to LOD value for each and detecting 
in all the cases the three allergenic proteins. 
 
 
Fig. SRM LC-ESI-MS/MS chromatogram of a blank red wine sample fortified with commercial 
fining agents (Protoclar® and egg-white powder) at 10 µg/mL  
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4. CONCLUSIONS 
The results described here allowed for the selection of peptide tag markers specific for the major red 
wine residuals allergens. The suitable selection of the biomarker peptides, the LC separation and the 
sample preparation protocol are crucial and constitute the basis for reliable confirmatory methods 
for the detection of allergens in food and beverage samples. As for red wine, an easy protein cut-off 
concentration protocol combined with size-exclusion-based purification was developed and 
proposed as reliable procedure. In comparison with a conventional PVPP, SE is able to provide 
improved protein recovery and extract purity. The sample workflow proposed combined with LC-
MS/MS analysis was proved sensitive enough to identify and quantify allergens in red wine protein 
extracts at very low levels (about mg protein/mL wine), making this method useful to assist in the 
protection of the health of allergic consumers. 
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